Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

National Cancer Institute

Aliases
National Cancer Institute (NCI)

972 clinical trials

Clinical trial
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 1 and Pharmacokinetic Study of Uproleselan (GMI-1271, NSC #801708) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome or Mixed Phenotype Acute Leukemia That Expresses E-selectin Ligand on the Cell Membrane and is in Second or Greater Relapse or That is Refractory to Relapse Therapy
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Status: Recruiting, Estimated PCD: 2028-05-01
Clinical trial
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Status: Not yet recruiting, Estimated PCD: 2027-07-30
Clinical trial
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma
Status: Recruiting, Estimated PCD: 2025-06-15
Clinical trial
Phase I/II Trial of PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
Status: Active (not recruiting), Estimated PCD: 2021-08-13
Clinical trial
A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors
Status: Recruiting, Estimated PCD: 2025-06-14
Clinical trial
Phase 2 Study of M6620 (VX-970) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer
Status: Active (not recruiting), Estimated PCD: 2020-06-15
Clinical trial
A Phase 1/2 Trial of Erlotinib and Onalespib Lactate in EGFR-Mutant Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2021-09-03
Clinical trial
Breast Imaging Screening Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-up Study
Status:
Clinical trial
A Phase 1 Study of ZEN003694 (ZEN-3694) in Combination With Cetuximab and Encorafenib in Patients With Refractory BRAF V600E Metastatic Colorectal Cancer
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase 1 Study of Lenalidomide in Combination With EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Phase Ib Study of Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency
Status: Recruiting, Estimated PCD: 2026-10-30
Clinical trial
A Phase II Study of Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
Status: Recruiting, Estimated PCD: 2025-11-24
Clinical trial
Phase 2 Trial of Encorafenib Plus Binimetinib for Patients With BRAF V600 Mutated Relapsed/Refractory HCL
Status: Recruiting, Estimated PCD: 2028-04-30
Clinical trial
Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
Status: Active (not recruiting), Estimated PCD: 2019-04-03
Clinical trial
Phase I Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Feasibility Multicenter Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Status: Not yet recruiting, Estimated PCD: 2025-11-29
Clinical trial
A Phase II Multicenter Study of Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)
Status: Not yet recruiting, Estimated PCD: 2027-10-01
Clinical trial
Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and Pembrolizumab (MK-3475) Compared to Pembrolizumab Alone for Mesothelin-Positive Malignant Pleural Mesothelioma
Status: Active (not recruiting), Estimated PCD: 2023-07-08
Clinical trial
An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2022-12-01
Clinical trial
Early Assessment of Treatment Response in AML Using FLT PET/CT Imaging
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
Phase I Trial of Radiotherapy Combined With Durvalumab Alone Plus Either Monalizumab or Oleclumab in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)
Status: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Completed, Estimated PCD: 2018-12-31
Clinical trial
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Status: Active (not recruiting), Estimated PCD: 2020-03-31
Clinical trial
Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2026-10-10
Clinical trial
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Status: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
Phase I Clinical Trial of M6620 (VX-970, Berzosertib) in Combination With the Topoisomerase I Inhibitor Irinotecan in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2023-03-07
Clinical trial
A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination With Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
Status: Withdrawn, Estimated PCD: 2024-01-31
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Status: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
FOLFOX in Combination With Binimetinib as 2nd Line Therapy for Patients With Advanced Biliary Tract Cancers With MAPK Pathway Alterations: A ComboMATCH Treatment Trial
Status: Recruiting, Estimated PCD: 2025-01-21
Clinical trial
A Phase 1 Study of MLN4924 (Pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase I Study of Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
Status: Completed, Estimated PCD: 2023-10-02
Clinical trial
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Terminated, Estimated PCD: 2023-11-15
Clinical trial
A Phase II Randomized Study Comparing Ibrutinib and Rituximab vs. Venetoclax and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL)
Status: Recruiting, Estimated PCD: 2028-03-31
Clinical trial
A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
Status: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
A Phase 2 Study of MLN4924 (Pevonedistat) in Combination With Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated With Immunotherapy
Status: Active (not recruiting), Estimated PCD: 2022-09-07
Clinical trial
Cell Harvest and Preparation for Surgery Branch Treatment Protocols
Status:
Clinical trial
Treatment and Natural History Study of Lymphomatoid Granulomatosis
Status: Active (not recruiting), Estimated PCD: 2030-02-01
Clinical trial
Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery
Status: Active (not recruiting), Estimated PCD: 2021-02-22
Clinical trial
A Phase Ib/II Multicenter Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS
Status: Not yet recruiting, Estimated PCD: 2025-07-01
Clinical trial
Immunogenicity of Nonavalent HPV Vaccine Administered Prior to Renal Transplantation in Adults: A Prospective, Single-Arm, Multi-Center Clinical Trial
Status: Active (not recruiting), Estimated PCD: 2024-03-04
Clinical trial
Phase I Trial of a Therapeutic DNA Vaccine for Chronic Hepatitis C Virus (HCV) Infection
Status: Active (not recruiting), Estimated PCD: 2020-03-04
Clinical trial
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
Status: Recruiting, Estimated PCD: 2029-05-15
Clinical trial
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
Status: Recruiting, Estimated PCD: 2027-06-30
Clinical trial
A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers
Status: Active (not recruiting), Estimated PCD: 2021-08-25
Clinical trial
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
Status: , Estimated PCD: 2029-12-31
Clinical trial
A Phase I/II Trial of Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
Status: Recruiting, Estimated PCD: 2027-04-05
Clinical trial
Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination With Azenosertib (ZN-c3) in HER2-Expressing/Amplified Cyclin E-Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors With HER2 Expression
Status: Not yet recruiting, Estimated PCD: 2026-03-31
Clinical trial
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Status: Recruiting, Estimated PCD: 2026-09-28
Clinical trial
A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy
Status: Active (not recruiting), Estimated PCD: 2023-06-30
Clinical trial
A Phase 2 Study of Human-Mouse Chimeric Anti-disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038) in Combination With Sargramostim (GM-CSF) in Patients With Recurrent Osteosarcoma
Status: Completed, Estimated PCD: 2020-03-31
Clinical trial
A Phase I/II Study of Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
Status: Recruiting, Estimated PCD: 2028-03-01
Clinical trial
A Phase 1 Study of Nivolumab in Combination With ASTX727 in B-Cell Lymphoma (NHL or HL) With an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Recruiting, Estimated PCD: 2027-06-28
Clinical trial
A Phase I Clinical Trial of CA-4948 in Combination With Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma
Status: , Estimated PCD: 2025-03-15
Clinical trial
Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Status: Terminated, Estimated PCD: 2020-09-29
Clinical trial
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Status: Active (not recruiting), Estimated PCD: 2022-09-01
Clinical trial
Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults With Refractory Solid Tumors, Lymphomas, or Myelodysplastic Syndromes
Status: Recruiting, Estimated PCD: 2024-12-15
Clinical trial
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2020-03-26
Clinical trial
Phase I/Ib Trial Evaluating the Safety and Efficacy of BET Inhibitor, ZEN003694 With PD-1 Inhibitor, Nivolumab With or Without CTLA-4 Inhibitor, Ipilimumab in Solid Tumors
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
Status: Active (not recruiting), Estimated PCD: 2025-10-31
Clinical trial
Refining Tamoxifen Dose for Premenopausal Breast Cancer Risk Reduction (RENAISSANCE): A Phase II Single Arm Trial
Status: Not yet recruiting, Estimated PCD: 2027-12-31
Clinical trial
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Phase I/II Trial of Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)
Status: Not yet recruiting, Estimated PCD: 2029-07-01
Clinical trial
A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Booster Doses of Vaccine
Status: Completed, Estimated PCD: 2023-05-25
Clinical trial
A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN00-3694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer
Status: Recruiting, Estimated PCD: 2026-04-30
Clinical trial
Randomized Phase 2 Study of Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
Status: Recruiting, Estimated PCD: 2027-10-31
Clinical trial
A Phase 1b/2 Study of Pinometostat in Combination With Standard Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia With MLL Rearrangement
Status: Terminated, Estimated PCD: 2022-11-14
Clinical trial
Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Status: Recruiting, Estimated PCD: 2028-10-01
Clinical trial
Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis
Status: Recruiting, Estimated PCD: 2025-05-29
Clinical trial
A Phase I Trial of Riluzole and Sorafenib in Patients With Advanced Solid Tumors and Melanoma
Status: Active (not recruiting), Estimated PCD: 2012-05-01
Clinical trial
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Status: Active (not recruiting), Estimated PCD: 2022-12-15
Clinical trial
MATCH Treatment Subprotocol Q: Ado-trastuzumab Emtansine in Patients With Tumors With HER2 Amplification (Except Breast and Gastric/Gastro-Esophageal Junction (GEJ) Adenocarcinomas)
Status: Active (not recruiting), Estimated PCD: 2019-03-09
Clinical trial
MATCH Treatment Subprotocol Z1A: Binimetinib in Patients With Tumors (Other Than Melanoma) With NRAS Mutations
Status: Active (not recruiting), Estimated PCD: 2019-05-03
Clinical trial
A Phase 2 Study of Nivolumab and Ipilimumab in Advanced Leiomyosarcoma of the Uterus
Status: Active (not recruiting), Estimated PCD: 2018-09-20
Clinical trial
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2033-12-30
Clinical trial
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 3 Tiragolumab + Atezolizumab
Status: Recruiting, Estimated PCD: 2026-10-15
Clinical trial
Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
Status: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
A Phase II Trial In Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, With Cross-Over at Disease Progression
Status: Active (not recruiting), Estimated PCD: 2023-11-06
Clinical trial
Phase I/II Study De-intensifying Exposure of Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HLA-haploidentical Hematopoietic Cell Transplantation for Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Status: Completed, Estimated PCD: 2017-11-30
Clinical trial
A Randomized and Placebo-Controlled Phase II Trial Targeting Dominant-Negative Missense Mutant P53 by Atorvastatin for Reducing the Risk of Longstanding Ulcerative Colitis-Associated Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants With AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial
Status: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial
Status: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults With Refractory Solid Tumors
Status: Completed, Estimated PCD: 2015-09-08
Clinical trial
MATCH Treatment Subprotocol S2: Phase II Study of Trametinib in Patients With Tumors With GNAQ or GNA11 Mutations
Status: Active (not recruiting), Estimated PCD: 2020-09-01
Clinical trial
NORM: Nodular Lymphocyte-Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase 2 Trial With Either Rituximab or Mosunetuzumab
Status: Recruiting, Estimated PCD: 2026-10-31
Clinical trial
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
Status: Completed, Estimated PCD: 2023-06-23
Clinical trial
Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial
Status: Recruiting, Estimated PCD: 2026-08-26
Clinical trial
Phase II Study Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Phase I/II Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Bone Marrow Transplantation Followed by GVHD Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV (PLWH)
Status: , Estimated PCD: 2026-07-30
Clinical trial
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Status: Active (not recruiting), Estimated PCD: 2028-12-31
Clinical trial
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma
Status: Active (not recruiting), Estimated PCD: 2019-02-15
Clinical trial
A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy
Status: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2021-04-30
Clinical trial
Phase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2028-07-03
Clinical trial
Phase I Study of TRC102 in Combination With Cisplatin and Pemetrexed in Patients With Advanced Solid Tumors / Phase II Study of TRC102 With Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin
Status: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
A Phase I/II Trial of Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High Grade Neuroendocrine Cancers
Status: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
A Phase 1 Study of Trametinib in Combination With Radiation Therapy for Brain Metastases
Status: Active (not recruiting), Estimated PCD: 2020-07-10
Clinical trial
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Status: Active (not recruiting), Estimated PCD: 2022-04-12
Clinical trial
Phase IIA, Single-Arm, Open- Label, Clinical Trial of Calcipotriene Plus 5-fluorouracil Immunotherapy for Skin Cancer Prevention in Organ Transplant Recipients
Status: Recruiting, Estimated PCD: 2027-02-01
Clinical trial
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Status: Active (not recruiting), Estimated PCD: 2019-12-31
Clinical trial
Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Vaccine in Patients With Newly Diagnosed Advanced Adenomas
Status: Active (not recruiting), Estimated PCD: 2017-01-27
Clinical trial
Phase I Study of AZD1775 (Adavosertib) With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients With Recurrent Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2021-07-29
Clinical trial
Phase I Trial of Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Status: Recruiting, Estimated PCD: 2028-06-01
Clinical trial
A Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor-Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI)
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism
Status: Not yet recruiting, Estimated PCD: 2027-12-01
Clinical trial
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Status: Recruiting, Estimated PCD: 2024-12-15
Clinical trial
Phase II Randomized Trial of Immunotherapy Versus Immunotherapy and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (IMMORTAL)
Status: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Status: Recruiting, Estimated PCD: 2029-06-30
Clinical trial
A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Status: Active (not recruiting), Estimated PCD: 2022-06-01
Clinical trial
A Phase II Study of Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinoma (BTC)
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Status: Recruiting, Estimated PCD: 2024-12-03
Clinical trial
A Phase 2 Study of DS-8201a (NSC# 807708) in Adolescents, or Young Adults With Recurrent HER2+ Osteosarcoma
Status: , Estimated PCD: 2025-03-31
Clinical trial
A Phase II Study of Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Status: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Status: Not yet recruiting, Estimated PCD: 2027-07-30
Clinical trial
A Phase I Trial of AT13387 in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN) Receiving Concurrent Radiation and Cisplatin
Status: Active (not recruiting), Estimated PCD: 2020-04-24
Clinical trial
A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)
Status: Completed, Estimated PCD: 2021-03-31
Clinical trial
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 2 Talazoparib and Temozolomide
Status: Recruiting, Estimated PCD: 2026-04-15
Clinical trial
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Status: Active (not recruiting), Estimated PCD: 2021-06-30
Clinical trial
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Status: Recruiting, Estimated PCD: 2025-04-02
Clinical trial
A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients With Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial
Status: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Randomized Phase 2 Trial to Evaluate the Efficacy of BCL-2 Inhibitor Therapy With Chemotherapy Compared to Chemotherapy Alone in Adult Patients With Newly Diagnosed T-Cell ALL and T-Cell Lymphoblastic Lymphoma
Status: Withdrawn, Estimated PCD: 2026-09-22
Clinical trial
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Phase I Study of Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
Status: Terminated, Estimated PCD: 2021-12-06
Clinical trial
A Pilot Study of MUC1 Vaccine in Current and Former Smokers at High Risk for Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2021-09-23
Clinical trial
MATCH Treatment Subprotocol Z1I: Phase II Study of AZD1775 in Patients With Tumors Containing BRCA1 and BRCA2 Mutations
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
Phase II Study of Enasidenib in IDH2-mutated Malignant Sinonasal and Skull Base Tumors
Status: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas
Status: Completed, Estimated PCD: 2022-10-22
Clinical trial
Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)
Status: Recruiting, Estimated PCD: 2027-07-01
Clinical trial
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Status: Recruiting, Estimated PCD: 2028-05-01
Clinical trial
A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination With Atezolizumab Compared to Atezolizumab Alone in Subjects With Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes Derived From Patients With Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen
Status: Recruiting, Estimated PCD: 2024-10-23
Clinical trial
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas
Status: Completed, Estimated PCD: 2017-06-21
Clinical trial
A Phase 1/2 Study of Nivolumab and Ipilimumab in Combination With Sirolimus and Prednisone in Kidney Transplant Recipients With Selected Unresectable or Metastatic Cutaneous Cancers
Status: Recruiting, Estimated PCD: 2027-01-31
Clinical trial
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Status: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2022-06-22
Clinical trial
A Phase I Study With an Expansion Cohort of Duvelisib and Nivolumab in Mycosis Fungoides (MF) and Sézary Syndrome (SS)
Status: Recruiting, Estimated PCD: 2025-05-03
Clinical trial
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Status: Not yet recruiting, Estimated PCD: 2032-03-31
Clinical trial
A Randomized Phase 2 Study of Atezolizumab in Combination With Cobimetinib Versus Atezolizumab Monotherapy in Participants With Unresectable Cholangiocarcinoma
Status: Completed, Estimated PCD: 2020-08-07
Clinical trial
A Phase I Study of Pomalidomide and Nivolumab in Patients With Virus-Associated Malignancies With or Without HIV
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Related and Unrelated Donor Hematopoietic Stem Cell Transplant for DOCK8 Deficiency
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Venetoclax in Combination With ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 Trial
Status: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) to (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger With High-Risk (Adverse) Acute Myeloid Leukemia; A MYELOMATCH Clinical Trial
Status: Recruiting, Estimated PCD: 2027-03-31
Clinical trial
A Study of Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease
Status: Active (not recruiting), Estimated PCD: 2024-06-24
Clinical trial
Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Cancers
Status: Recruiting, Estimated PCD: 2025-01-15
Clinical trial
A Prospective Randomized and Phase II Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Status: , Estimated PCD: 2025-06-16
Clinical trial
A Phase 1 and Randomized Phase 2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma
Status: , Estimated PCD: 2026-06-30
Clinical trial
A Phase I Study of ABT-888 in Combination With Cyclophosphamide in Solid Tumors or Non-Hodgkin Lymphoma
Status: Active (not recruiting), Estimated PCD: 2021-09-03
Clinical trial
Randomized, Double-Blind, Placebo-Controlled Trial of Meriva® (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis
Status: Active (not recruiting), Estimated PCD: 2022-10-06
Clinical trial
A Phase I Single-arm, Multicenter Pilot Study Aimed at Validating γ-OHPdG as a Biomarker and Testing the Effects of Polyphenon E on Its Levels in Patients With Cirrhosis
Status: Active (not recruiting), Estimated PCD: 2023-06-16
Clinical trial
A Phase 1 and Pharmacokinetic Study of Uproleselan (GMI-1271, NSC #801708) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia Myelodysplastic Syndrome or Mixed Phenotype Acute Leukemia That Expresses E-Selectin Ligand on the Cell Membrane and is in Second or Greater Relapse or That is Refractory to Relapse Therapy
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Status: Active (not recruiting), Estimated PCD: 2021-12-31
Clinical trial
Nilotinib and Paclitaxel in Patients With Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial
Status: , Estimated PCD: 2025-07-01
Clinical trial
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Status: Recruiting, Estimated PCD: 2026-04-11
Clinical trial
A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Status: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-07-15
Clinical trial
Phase 1 Trial of CA-4948 in Combination With Pembrolizumab to Overcome Resistance to PD-1/PD-L1 Blockade in Metastatic Urothelial Cancer
Status: Not yet recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Phase I/II Trial of BMS-986253 in Myelodysplastic Syndromes
Status: Terminated, Estimated PCD: 2023-02-02
Clinical trial
A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
Status: Recruiting, Estimated PCD: 2027-08-15
Clinical trial
A Phase II, Open-Label Trial of PT-112 in Subjects With Thymoma and Thymic Carcinoma
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in Combination With Leuprolide Acetate and Exemestane in Recurrent Adult-Type Ovarian Granulosa Cell Tumor
Status: , Estimated PCD: 2027-05-31
Clinical trial
A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors
Status: Completed, Estimated PCD: 2020-12-31
Clinical trial
A Pilot Study of Long Term TARP Vaccination Using A Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccine in Previously Vaccinated Men on NCI 09-C-0139.
Status: Completed, Estimated PCD: 2022-03-25
Clinical trial
A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) With Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer
Status: Active (not recruiting), Estimated PCD: 2024-10-31
Clinical trial
A Phase II Trial of Azacitidine (NSC-102816) Plus Gemtuzumab Ozogamicin (NSC-720568) as Induction and Post-Remission Therapy in Patients of Age 60 and Older With Previously Untreated Non-M3 Acute Myeloid Leukemia
Status: Active (not recruiting), Estimated PCD: 2013-06-01
Clinical trial
A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Status: , Estimated PCD: 2026-01-31
Clinical trial
Phase 2 Study of Copanlisib in Combination With Nivolumab in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2022-11-18
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
Status: Active (not recruiting), Estimated PCD: 2023-03-31
Clinical trial
A Randomized Phase 2 Study of Cediranib in Combination With Olaparib Versus Olaparib Alone in Men With Metastatic Castration Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2023-03-14
Clinical trial
Phase II Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) With High-Risk Genomic Features
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Status: Completed, Estimated PCD: 2021-06-30
Clinical trial
Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
Status: Not yet recruiting, Estimated PCD: 2033-01-01
Clinical trial
Phase 1 Umbrella Trial of Erlotinib In Combination With Select Tyrosine Kinase Inhibitors In Adult Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-01-05
Clinical trial
A Phase 1/1b Dose Escalation Study of Abemaciclib and Olaparib for Recurrent Platinum-Resistant Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab
Status: Recruiting, Estimated PCD: 2024-12-27
Clinical trial
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
MATCH Treatment Subprotocol S1: Phase II Study of Trametinib in Patients With Tumors With NF1 Mutations
Status: Active (not recruiting), Estimated PCD: 2020-06-30
Clinical trial
Phase II Study Evaluating the Efficacy of M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma
Status: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Olaparib Plus Low-Dose Alpelisib for Breast Cancer: A ComboMATCH Treatment Trial
Status: Withdrawn, Estimated PCD: 2025-04-30
Clinical trial
A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2023-05-09
Clinical trial
Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
Status: Completed, Estimated PCD: 2016-01-02
Clinical trial
A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma
Status: Completed, Estimated PCD: 2018-11-02
Clinical trial
Phase I Trial of 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (Oportuzumab Monatox, VB4-845) in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
Status: Completed, Estimated PCD: 2022-08-01
Clinical trial
A Phase 1/2 Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (SCT)
Status: Active (not recruiting), Estimated PCD: 2022-06-30
Clinical trial
Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers
Status: Active (not recruiting), Estimated PCD: 2016-12-31
Clinical trial
Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Paclitaxel and Carboplatin With Ipatasertib as Initial Therapy of Ovarian Cancer PTMA 100805
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase IB Study of the Combination of AZD6244 Hydrogen Sulfate (Selumetinib) and Cyclosporin A (CsA) in Patients With Advanced Solid Tumors With an Expansion Cohort in Metastatic Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2017-01-31
Clinical trial
Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study ("Estudio de Comparacion de Una y Dos Dosis de Vacunas Contra el Virus de Papiloma Humano (VPH)")
Status: , Estimated PCD: 2025-08-01
Clinical trial
Phase I Study of Z-Endoxifen as a Hormonal Therapy for Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2017-03-05
Clinical trial
A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
Status: Recruiting, Estimated PCD: 2026-12-30
Clinical trial
A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
Status: Active (not recruiting), Estimated PCD: 2025-02-15
Clinical trial
A Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH) Mutant Solid Tumors
Status: , Estimated PCD: 2025-03-01
Clinical trial
Phase I Trial of OSI-774 and CPT-11 in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2013-09-13
Clinical trial
Phase I/Ib Trial of ATR Inhibitor BAY 1895344 in Combination With FOLFIRI in GI Malignancies With a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers
Status: Active (not recruiting), Estimated PCD: 2024-03-29
Clinical trial
A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
Status: Recruiting, Estimated PCD: 2026-02-28
Clinical trial
A Randomized Phase II Study of AMG 510 (Sotorasib) With or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Transanal Irrigation - Best Treatment Possibility for Low Anterior Resection Syndrome? Multicenter, Randomized Clinical Trial
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Completed, Estimated PCD: 2015-07-30
Clinical trial
Phase I/II Study of T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
Status: Terminated, Estimated PCD: 2021-06-28
Clinical trial
A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2024-07-17
Clinical trial
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Status: Active (not recruiting), Estimated PCD: 2019-06-30
Clinical trial
A Phase II Study of LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Terminated, Estimated PCD: 2020-06-17
Clinical trial
A Randomized Phase II Trial Comparing the Combination of PI3K Inhibitor Copanlisib (BAY 80-6946) and PARP Inhibitor Olaparib (AZD2281) to Standard Chemotherapy in Patients With Recurrent Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Progressed Through Prior PARP Inhibitor Therapy
Status: Withdrawn, Estimated PCD: 2023-03-17
Clinical trial
A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma
Status: Recruiting, Estimated PCD: 2026-04-30
Clinical trial
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
Status: Completed, Estimated PCD: 2020-09-24
Clinical trial
Phase I Randomized Study of MAGE-12 Peptide Vaccine in Patients With Refractory Metastatic Cancer Expressing MAGE-12 Antigen
Status:
Clinical trial
A Phase 2 Study of M6620 (VX-970, Berzosertib) in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination With the CDK4/6 Inhibitor Abemaciclib in Patients With NUT Carcinoma, Breast Cancer and Other Solid Tumors
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers
Status: Active (not recruiting), Estimated PCD: 2022-10-25
Clinical trial
Phase I Study of The Combination of Bortezomib and Sorafenib Followed by Decitabine in Patients With Acute Myeloid Leukemia
Status: Active (not recruiting), Estimated PCD: 2015-11-06
Clinical trial
A Multicenter Phase II Study of Pomalidomide Monotherapy in Kaposi Sarcoma
Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239) and Bendamustine in Patients With Untreated Follicular Lymphoma
Status: Active (not recruiting), Estimated PCD: 2017-05-24
Clinical trial
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase 1 Study of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase 1 Study of Entinostat in Combination With Atezolizumab / Carboplatin / Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer
Status: Completed, Estimated PCD: 2021-12-30
Clinical trial
A Phase II Trial of Osimertinib (AZD9291) With or Without Bevacizumab in Patients With EGFR Mutation Positive NSCLC and Brain Metastases
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Status: Recruiting, Estimated PCD: 2027-10-31
Clinical trial
A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2020-12-31
Clinical trial
A Randomized Phase II Trial Evaluating Chemotherapy Plus Atezolizumab vs Chemotherapy Plus Bevacizumab and Atezolizumab in Advanced Combined Hepatocellular Carcinoma-Cholangiocarcinoma
Status: Active (not recruiting), Estimated PCD: 2025-01-31
Clinical trial
A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2021-04-22
Clinical trial
A Phase I Trial of Inhaled Iloprost for the Prevention of Lung Cancer in Former Smokers
Status: Completed, Estimated PCD: 2020-03-05
Clinical trial
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2023-04-14
Clinical trial
Drug Distribution and Pharmacodynamic Study of Pulsatile Lapatinib in Surgically Accessible EGFR-Amplified Recurrent High-Grade Glioma
Status: Active (not recruiting), Estimated PCD: 2021-10-19
Clinical trial
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Statin Therapy to Reduce Disease Progression From Liver Cirrhosis to Cancer
Status: Active (not recruiting), Estimated PCD: 2023-05-03
Clinical trial
A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men With Metastatic Castration Resistant Prostate Cancer
Status: Completed, Estimated PCD: 2022-09-28
Clinical trial
NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer
Status: Withdrawn, Estimated PCD: 2031-05-10
Clinical trial
A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer
Status: Not yet recruiting, Estimated PCD: 2032-09-01
Clinical trial
MATCH Treatment Subprotocol Z1M: Phase 2 Study of Nivolumab and BMS-986016 (Relatlimab) in Patients With LAG-3+ Tumors With Mismatch Repair Deficiency (MMR-d) After Progression on Anti-PD-1/PD-L1 Therapy
Status: Withdrawn, Estimated PCD: 2023-01-17
Clinical trial
A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 in Combination With Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers (10041848, 10008224, 10008238, 10046888, 10014735)
Status: Terminated, Estimated PCD: 2022-05-10
Clinical trial
Phase II Study of Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.
Status: Withdrawn, Estimated PCD: 2022-01-01
Clinical trial
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Status: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
A Phase II Trial Evaluating 18F-Fluciclovine PET/CT in Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-12-06
Clinical trial
A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Phase I/II Study of M9241 With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and M9241 With Docetaxel in Castration Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase II Trial Evaluating Nivolumab In Patients With IDH-Mutant Gliomas With And Without Hypermutator Phenotype
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer - A Collaborative Study of NRG Oncology and KROG
Status: Completed, Estimated PCD: 2019-12-30
Clinical trial
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
Phase II Study of Disulfiram and Cisplatin in Refractory TGCTs.
Status: Completed, Estimated PCD: 2021-09-30
Clinical trial
A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in Patients With Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer
Status: Active (not recruiting), Estimated PCD: 2023-10-31
Clinical trial
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Phase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases
Status: Active (not recruiting), Estimated PCD: 2022-08-19
Clinical trial
Phase 1 Study of Copanlisib With Dose-adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
Status: Completed, Estimated PCD: 2023-11-30
Clinical trial
NCI 10147: A Phase II Randomized Study of Topotecan/Carboplatin With or Without Veliparib in Advanced Myeloproliferative Disorders and Chronic Myelomonocytic Leukemia (CMML)
Status: Active (not recruiting), Estimated PCD: 2023-05-31
Clinical trial
A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma
Status: Completed, Estimated PCD: 2020-09-30
Clinical trial
Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Clinical, Histopathologic, and Genomic Analysis
Status: Completed, Estimated PCD: 2017-09-05
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes
Status: Active (not recruiting), Estimated PCD: 2023-03-31
Clinical trial
Phase II Study of FR901228 in Patients With Refractory or Progressive Small Cell or Non-Small Cell Lung Cancer
Status: Completed
Clinical trial
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
Status: Recruiting, Estimated PCD: 2028-01-10
Clinical trial
A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
Status: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2021-06-19
Clinical trial
A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, With or Without Atezolizumab in Triple Negative Breast Cancer (TNBC)
Status: Active (not recruiting), Estimated PCD: 2019-12-18
Clinical trial
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Phase 2 Study of GDC-0449 in Patients With Advanced Chondrosarcomas
Status: Active (not recruiting), Estimated PCD: 2018-06-30
Clinical trial
A Dose Escalation Phase I Trial of the Safety and Immunogenicity of RG1-VLP, a Candidate Broadly Protective Vaccine for the Prevention of HPV-Associated Cancer
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
Status: Recruiting, Estimated PCD: 2027-10-30
Clinical trial
A Phase 1 Study of the Polymerase Theta (POLQ) Inhibitor Novobiocin in BRCA-Mutant and Other DNA Damage Repair-Deficient Solid Tumors
Status: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
Phase I/II Trial of Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer (EC)
Status: , Estimated PCD: 2026-12-31
Clinical trial
Phase I/II Trial of Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
Status: Active (not recruiting), Estimated PCD: 2022-07-26
Clinical trial
A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
Surgical Window of Opportunity Study of Megestrol Acetate Compared With Megestrol Acetate and Metformin for Endometrial Intraepithelial Neoplasia.
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
Randomized Phase II Trial of Topotecan Plus M6620 (VX-970, Berzosertib) vs. Topotecan Alone in Patients With Relapsed Small-Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2022-12-19
Clinical trial
A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
Status: Active (not recruiting), Estimated PCD: 2023-05-26
Clinical trial
Phase I Study of Doxorubicin HCl Liposome in Pediatric Patients With Refractory Solid Tumors
Status:
Clinical trial
Pilot Trial Evaluating Viral Protein Production From the Combination of Reolysin and Carfilzomib in Multiple Myeloma
Status: Completed, Estimated PCD: 2021-05-05
Clinical trial
A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for CD25 Positive Hairy Cell Leukemia
Status: Completed, Estimated PCD: 2016-08-24
Clinical trial
Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer
Status: Active (not recruiting), Estimated PCD: 2024-11-30
Clinical trial
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Status: Active (not recruiting), Estimated PCD: 2019-05-01
Clinical trial
A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Status: Active (not recruiting), Estimated PCD: 2018-08-07
Clinical trial
Randomized Phase II Trial of Encorafenib and Cetuximab With or Without Nivolumab (NSC #748726) for Patients With Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Status: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations
Status: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)
Status: Active (not recruiting), Estimated PCD: 2023-08-06
Clinical trial
Phase I/II Study of PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
Status: Completed, Estimated PCD: 2023-06-20
Clinical trial
Docetaxel and Prostvac for Metastatic Castration Sensitive Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2022-07-01
Clinical trial
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Status: Active (not recruiting), Estimated PCD: 2023-06-23
Clinical trial
A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult With Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
Status: Active (not recruiting), Estimated PCD: 2023-08-04
Clinical trial
Eradicating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial
Status: Not yet recruiting, Estimated PCD: 2025-01-31
Clinical trial
A Phase III Randomized, Double-Blind Study of Maintenance Therapy With CC-5013 (NSC # 703813) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2012-12-31
Clinical trial
18F-DCFPyL PET/CT in Hepatocellular Carcinoma
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
MATCH Treatment Subprotocol Z1H: Phase II Study of Copanlisib in Patients With Tumors With Deleterious PTEN Sequencing Result and PTEN Expression by IHC
Status: Active (not recruiting), Estimated PCD: 2024-11-15
Clinical trial
A Phase Ib/II Clinical Trial of Nous-209 for Recurrent Neoantigen Immunogenicity and Cancer Immune Interception in Lynch Syndrome
Status: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2018-10-31
Clinical trial
A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
Status: Recruiting, Estimated PCD: 2029-12-31
Clinical trial
A Phase II Trial of Focal Ultrahypofractionated Stereotactic Radiation Therapy for the Treatment of Unifocal Prostate Cancer
Status: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers
Status: Recruiting, Estimated PCD: 2026-04-21
Clinical trial
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2020-05-05
Clinical trial
A Phase I/II Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; Hydrogen Sulfate in Children With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
Randomized Phase II Study of Carboplatin and Paclitaxel +/- Cetuximab, in Advanced and/or Recurrent Cervical Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase III Randomized, Double-Blind Trial of Chemoembolization With or Without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients With and Without Vascular Invasion
Status: Completed, Estimated PCD: 2021-02-11
Clinical trial
A Phase I/II Trial of Cetuximab in Combination With Interleukin-12 Administered to Patients With Unresectable Primary or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Active (not recruiting), Estimated PCD: 2015-09-29
Clinical trial
Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas
Status: Recruiting, Estimated PCD: 2029-06-01
Clinical trial
Phase II Trial of 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase IIa, Placebo-Controlled, Randomized Study of Daily Obeticholic Acid (OCA) to Reduce Intestinal Polyp Burden in Familial Adenomatous Polyposis (FAP)
Status: Recruiting, Estimated PCD: 2026-01-31
Clinical trial
Metformin for Chemoprevention of Lung Cancer in High-Risk Overweight or Obese Individuals
Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients With Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors
Status: Terminated, Estimated PCD: 2021-07-28
Clinical trial
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Status: , Estimated PCD: 2025-12-01
Clinical trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination With Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-01-30
Clinical trial
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Status: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification
Status: Completed, Estimated PCD: 2022-10-31
Clinical trial
Phase I Study of Ixabepilone and Temsirolimus in Adult Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2018-06-26
Clinical trial
Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults With Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (CNF)
Status: Completed, Estimated PCD: 2022-11-05
Clinical trial
Phase II Evaluation of Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 2 Study of Darolutamide in Combination With Leuprolide Acetate in Hormone-Therapy Naive Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer
Status: Recruiting, Estimated PCD: 2027-04-11
Clinical trial
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-08-30
Clinical trial
A Phase 1 Study of IPdR in Combination With Capecitabine and Radiotherapy in Rectal Cancer
Status: Terminated, Estimated PCD: 2023-01-18
Clinical trial
A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Prospective Randomized Phase II Trial of Pazopanib (NSC #737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Active (not recruiting), Estimated PCD: 2019-03-05
Clinical trial
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation With JSP191-Based Conditioning in Participants With GATA2 Deficiency
Status: Recruiting, Estimated PCD: 2031-07-31
Clinical trial
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Active (not recruiting), Estimated PCD: 2013-02-15
Clinical trial
GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262
Status: Active (not recruiting), Estimated PCD: 2015-12-01
Clinical trial
Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Status: Recruiting, Estimated PCD: 2027-07-01
Clinical trial
A Randomized Phase II/III Trial of "Novel Therapeutics" Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
Status: Active (not recruiting), Estimated PCD: 2023-08-01
Clinical trial
MITO END-3: A Randomized Phase II Trial of Carboplatin+Paclitaxel Compared to Carboplatin+Paclitaxel+Avelumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
MATCH Treatment Subprotocol E: Osimertinib (AZD9291) in Patients With Tumors Having EGFR T790M Mutations or Rare Activating Mutations of EGFR
Status: Active (not recruiting), Estimated PCD: 2024-05-26
Clinical trial
Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Cancers
Status: Recruiting, Estimated PCD: 2027-01-15
Clinical trial
Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer
Status: Active (not recruiting), Estimated PCD: 2022-05-01
Clinical trial
A Phase 2 Study of Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
Status: Active (not recruiting), Estimated PCD: 2027-01-01
Clinical trial
A Phase I Trial of ABT-263 (Navitoclax), a Bcl-2 Inhibitor, and Sorafenib (Nexavar) in Patients With Relapsed or Refractory Solid Organ Tumors
Status: Active (not recruiting), Estimated PCD: 2022-11-30
Clinical trial
A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
Status: Recruiting, Estimated PCD: 2027-12-15
Clinical trial
Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults and Pediatric Patients With Refractory Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-27
Clinical trial
Phase I Study of GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase I Pilot Study of Vaccine Therapy With Tumor-Specific Mutated Ras Peptides in the Adjuvant Setting in Patients With Colorectal, Pancreatic, or Lung Cancer
Status:
Clinical trial
Phase II Study of Bladder-SparIng ChemoradiatioN With Durvalumab in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Status: Active (not recruiting), Estimated PCD: 2026-06-30
Clinical trial
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Active (not recruiting), Estimated PCD: 2012-01-12
Clinical trial
Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2020-06-01
Clinical trial
Phase I Trial of Image Guided Focally Dose Escalated Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
Status: Active (not recruiting), Estimated PCD: 2023-05-03
Clinical trial
A Phase 1 Study of Ipilimumab in Combination With Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Phase 1/2 Study of Daratumumab, Bortezomib, Dexamethasone With or Without Venetoclax in Relapsed/Refractory Multiple Myeloma With Assessment for t(11;14) Status
Status: Withdrawn, Estimated PCD: 2020-05-28
Clinical trial
A Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma
Status: Active (not recruiting), Estimated PCD: 2015-05-11
Clinical trial
Phase IIA Trial of Acolbifene (20 mg) vs Low Dose Tamoxifen (5 mg) in Pre-Menopausal Women at High Risk for Development of Breast Cancer
Status: Not yet recruiting, Estimated PCD: 2026-09-01
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions
Status: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
Feasibility of Evaluating Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Status: Active (not recruiting), Estimated PCD: 2023-10-04
Clinical trial
A Phase II/III Trial of Durvalumab and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
Status: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)
Status: Recruiting, Estimated PCD: 2025-08-04
Clinical trial
Phase 1 Trial of ONC201 for Chemoprevention of Colorectal Cancer
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
Phase II Randomized Study of CD34+ Derived or Peripheral Monocyte Derived Dendritic Cells Pulsed With MART-1 and gp100 Melanoma Antigens in Patients With High Risk Stage III or Completely Resected Metastatic Melanoma
Status: Completed
Clinical trial
A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2022-07-07
Clinical trial
A Phase 1/2 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774
Status: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
A Phase II Study of N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer
Status: Withdrawn, Estimated PCD: 2024-04-01
Clinical trial
A Phase I Clinical Trial of Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2023-09-29
Clinical trial
A Phase I Trial of Ibrutinib Plus PD 0332991 (Palbociclib) in Patients With Previously Treated Mantle Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2018-06-25
Clinical trial
MLN9708 (Ixazomib) and MLN4924 (Pevonedistat) in Relapsed/Refractory Multiple Myeloma Patients: A Phase 1b Trial
Status: Completed, Estimated PCD: 2022-09-12
Clinical trial
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Status: Recruiting, Estimated PCD: 2025-02-28
Clinical trial
Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
A Phase 2 Study of M1774 in Refractory SPOP-Mutant Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-04-25
Clinical trial
A Phase 1 Study of Olaparib in Combination With Durvalumab (MEDI4736) and Concurrent Radiation Therapy Following First-Line Chemotherapy in Locally Advanced Unresectable Pancreatic Cancer
Status: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
Evaluating Intermittent Dosing of Aspirin for Colorectal Cancer Chemoprevention
Status: Active (not recruiting), Estimated PCD: 2023-01-31
Clinical trial
An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2017-11-10
Clinical trial
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Status: Active (not recruiting), Estimated PCD: 2026-12-28
Clinical trial
Phase II Randomized Study of High-Dose Ketoconazole With or Without Alendronate Sodium in Patients With Androgen-Independent Metastastic Adenocarinoma of the Prostate
Status: Terminated
Clinical trial
A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2021-07-31
Clinical trial
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
Status: Active (not recruiting), Estimated PCD: 2023-03-31
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
Status: Active (not recruiting), Estimated PCD: 2022-03-31
Clinical trial
Phase Ib/II Study of EPA-Based EphA2 Targeted Therapy for Patients With Metastatic Triple-Negative Inflammatory Breast Cancer
Status: Terminated, Estimated PCD: 2023-12-19
Clinical trial
Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of M6620 (VX-970, Berzosertib) When Combined With Whole Brain Radiotherapy (WBRT) in Patients With Brain Metastases From Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2021-08-23
Clinical trial
Phase II Study of DNA Encoding the gp100 Antigen Alone or in Combination With Interleukin-2 in Patients With Recurrent Metastatic Melanoma
Status: Completed
Clinical trial
Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination With Neratinib in Solid Tumors With HER2 Alterations
Status: Recruiting, Estimated PCD: 2024-06-17
Clinical trial
A Phase II Study of Decitabine in Myelofibrosis
Status: Active (not recruiting), Estimated PCD: 2008-07-01
Clinical trial
Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid�) Alone and in Combination With Epoetin Alfa (Procrit�) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Status: Active (not recruiting), Estimated PCD: 2019-07-08
Clinical trial
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Status: Recruiting, Estimated PCD: 2031-04-28
Clinical trial
Phase I Sequential Trial of Agents Against DNA Repair (STAR)
Status: Active (not recruiting), Estimated PCD: 2023-02-22
Clinical trial
Clinical Evaluation of ASTX727 in Combination With Venetoclax All-Oral Therapy vs Standard of Care Cytarabine and Anthracycline Induction Chemotherapy for Younger FLT3WT Patients With ELN High- Risk Acute Myeloid Leukemia
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Neo-adjuvant Chemo and Immunotherapy With Durvalumab (MEDI4736) and Tremelimumab (MEDI1123) In The Pre-operAtive Treatment of Locally Advanced cholangIOcarciNoma: an Exploratory and Translational Study.
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
VADIS Trial: Phase II Trial of Nelipeimut-S Peptide Vaccine in Women With DCIS of the Breast
Status: Completed, Estimated PCD: 2019-07-22
Clinical trial
A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients With Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy
Status: , Estimated PCD: 2030-03-09
Clinical trial
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Status: Active (not recruiting), Estimated PCD: 2023-03-31
Clinical trial
A Phase 1/1b Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Recombinant Human IL-7-hyFc (NT-I7) in Older Subjects Following Chemotherapy
Status: Withdrawn, Estimated PCD: 2023-11-01
Clinical trial
Phase II Randomized Study of Monoclonal Antibody VEGF in Patients With Unresectable Advanced Renal Cell Cancer
Status: Completed
Clinical trial
A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
MATCH Treatment Subprotocol R: Phase II Study of Trametinib in Patients With BRAF Fusions, or With NonV600E, Non-V600K BRAF Mutations
Status: Active (not recruiting), Estimated PCD: 2019-03-18
Clinical trial
An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Status: Recruiting, Estimated PCD: 2025-10-31
Clinical trial
Optimizing Antibody-Drug Conjugate Therapy Through Molecular Analysis for Therapy Choice (ADC MATCH)
Status: Not yet recruiting, Estimated PCD: 2024-10-31
Clinical trial
A Phase I Trial of the P97 Inhibitor CB-5339 in Patients With Advanced Solid Tumors and Lymphomas
Status: Withdrawn, Estimated PCD: 2021-07-12
Clinical trial
Clinical Study of Bioactivity of Low Dose Apalutamide in Prostate Cancer Patients Scheduled for Prostatectomy
Status: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
Phase II Randomized, Double-Blind, Placebo-Controlled, Crossover Trial of Broccoli Seed and Sprout Extract (BSSE) to Evaluate Detoxification of Carcinogens in Firefighters
Status: , Estimated PCD: 2025-11-01
Clinical trial
A Pilot Study of the Immunological Effects of Neo-Adjuvant INCB024360 in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Status: Active (not recruiting), Estimated PCD: 2016-03-31
Clinical trial
Phase II Study of Flt3 Ligand Alone or in Combination With Melanoma Peptide Immunization in Patients With Metastatic Melanoma or Renal Cell Cancer
Status: Completed
Clinical trial
A Phase I/II Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell Cancers
Status: Active (not recruiting), Estimated PCD: 2021-02-24
Clinical trial
Phase II Trial of VB-111 in Combination With Nivolumab in Patients With Metastatic Colorectal Cancer (mCRC).
Status: Completed, Estimated PCD: 2022-04-12
Clinical trial
Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)
Status: Active (not recruiting), Estimated PCD: 2016-06-01
Clinical trial
Phase II Study of Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Completed, Estimated PCD: 2020-06-30
Clinical trial
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma
Status: Active (not recruiting), Estimated PCD: 2022-11-28
Clinical trial
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Role of Lisinopril in Preventing The Progression of Non-Alcoholic Fatty Liver Disease (NAFLD): Relief-NAFLD
Status: Recruiting, Estimated PCD: 2024-10-30
Clinical trial
A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
MATCH Treatment Subprotocol Y: AZD5363 in Patients With Tumors With AKT Mutations
Status: Active (not recruiting), Estimated PCD: 2019-11-08
Clinical trial
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
Status: Recruiting, Estimated PCD: 2028-12-30
Clinical trial
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
Status: Recruiting, Estimated PCD: 2028-12-31
Clinical trial
MATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients With Tumors With HER2 Activating Mutations
Status: Active (not recruiting), Estimated PCD: 2021-01-22
Clinical trial
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Status: Completed, Estimated PCD: 2019-12-23
Clinical trial
Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection
Status: Active (not recruiting), Estimated PCD: 2025-11-02
Clinical trial
A Phase 1 Study of AZD1775 (MK-1775) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas
Status: Completed, Estimated PCD: 2020-12-31
Clinical trial
Randomized Phase III Trial of Chemotherapy vs. Pembrolizumab Plus Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma
Status: Withdrawn, Estimated PCD: 2028-06-30
Clinical trial
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Status: Active (not recruiting), Estimated PCD: 2019-04-30
Clinical trial
DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma
Status: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Status: Active (not recruiting), Estimated PCD: 2027-06-01
Clinical trial
A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors
Status: Completed, Estimated PCD: 2017-02-07
Clinical trial
Phase 2 Trial of Fulvestrant and Binimetinib in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Inactivating or Inferred Inactivating NF1 Alterations: A ComboMATCH Treatment Trial
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
Status: Recruiting, Estimated PCD: 2030-07-01
Clinical trial
Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma
Status: Completed, Estimated PCD: 2017-01-30
Clinical trial
Phase 1/2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
Status: Recruiting, Estimated PCD: 2025-03-10
Clinical trial
A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel
Status: Active (not recruiting), Estimated PCD: 2022-07-25
Clinical trial
A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
A Prospective, Single-Arm, Open-Label, Non-Randomized, Phase IIA Trial of a Nonavalent Prophylactic HPV Vaccine to Assess Immunogenicity of a Prime and Deferred-Booster Dosing Schedule Among 9-11 Year-Old Girls and Boys
Status: Active (not recruiting), Estimated PCD: 2020-02-06
Clinical trial
A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients With Previously Treated Non-Squamous NSCLC
Status: Completed, Estimated PCD: 2022-05-09
Clinical trial
Phase I/II Study of Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
Status: Active (not recruiting), Estimated PCD: 2018-12-28
Clinical trial
MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients With Tumors With BRAF Fusions, or With Non-V600E, Non-V600K BRAF Mutations
Status: Active (not recruiting), Estimated PCD: 2025-03-24
Clinical trial
A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair Defects
Status: Recruiting, Estimated PCD: 2024-08-21
Clinical trial
A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
Status: Recruiting, Estimated PCD: 2025-04-07
Clinical trial
A Phase 2 Study of BAY 43-9006 for Imatinib- and Sunitinib Resistant Gastrointestinal Stromal Tumor
Status: Active (not recruiting), Estimated PCD: 2010-02-11
Clinical trial
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma
Status: Recruiting, Estimated PCD: 2025-06-15
Clinical trial
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: , Estimated PCD: 2015-02-20
Clinical trial
Phase Ib/II Trial of Copanlisib in Combination With Trastuzumab and Pertuzumab After Induction Treatment of HER2 Positive (HER2+) Metastatic Breast Cancer (MBC) With PIK3CA Mutation or PTEN Mutation
Status: Terminated, Estimated PCD: 2022-04-29
Clinical trial
A Sequential Window of Opportunity Trial of Anti-PD-L1/TGF-beta Trap (M7824 ) Alone and in Combination With TriAd Vaccine, and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection.
Status: Completed, Estimated PCD: 2021-08-24
Clinical trial
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Status: Active (not recruiting), Estimated PCD: 2023-01-26
Clinical trial
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Status: Active (not recruiting), Estimated PCD: 2023-06-30
Clinical trial
Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)
Status: Completed, Estimated PCD: 2023-02-07
Clinical trial
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Recruiting, Estimated PCD: 2027-06-29
Clinical trial
Obeticholic Acid for Prevention in Barrett's Esophagus
Status: Recruiting, Estimated PCD: 2025-09-29
Clinical trial
A Phase 1b Trial of M3814 (Peposertib) in Combination With Lutetium 177 Dotatate for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Status: Active (not recruiting), Estimated PCD: 2024-06-04
Clinical trial
Phase Ib Study of Copanlisib in Combination With Nivolumab or With Nivolumab and Ipilimumab
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
MATCH Treatment Subprotocol F: Crizotinib in Patients With Tumors (Other Than Adenocarcinoma of Lung or ALCL) With ALK Rearrangements
Status: Active (not recruiting), Estimated PCD: 2020-03-20
Clinical trial
A Phase I Trial of Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
Status: Active (not recruiting), Estimated PCD: 2023-12-29
Clinical trial
A Pilot Study of Nivolumab in Combination With Decitabine and Venetoclax in TP53-Mutated Acute Myeloid Leukemia
Status: Active (not recruiting), Estimated PCD: 2022-09-06
Clinical trial
Phase I/II Trial of PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Status: Recruiting, Estimated PCD: 2028-11-14
Clinical trial
Randomized Trial of Cladribine (CdA) With Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Mutations in GATA2 or the MonoMAC Syndrome
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase IB and Randomized Open-Label Phase II Study of Berzosertib (M6620, VX-970) in Combination With Carboplatin/Gemcitabine/Pembrolizumab in Patients With Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer of Squamous Cell Histology
Status: Active (not recruiting), Estimated PCD: 2024-03-31
Clinical trial
An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid(TM))(MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy
Status: Active (not recruiting), Estimated PCD: 2014-01-18
Clinical trial
A Phase II Study of the PARP Inhibitor Olaparib in Combination With the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
Status: Active (not recruiting), Estimated PCD: 2020-08-01
Clinical trial
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2023-04-13
Clinical trial
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Status: Recruiting, Estimated PCD: 2027-04-30
Clinical trial
Phase I/II Trial of Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Status: Not yet recruiting, Estimated PCD: 2030-01-01
Clinical trial
Phase I/Ib Study of AKT Inhibitor Ipatasertib With Chemoradiation for Locally Advanced Head and Neck Cancer
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2025-03-31
Clinical trial
A Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Advanced NSCLC Patients
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma
Status: Active (not recruiting), Estimated PCD: 2022-10-01
Clinical trial
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2023-02-01
Clinical trial
A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers
Status: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
A Phase 1/2 Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination With Azacitidine in Patients With the Myelodysplastic Syndrome (MDS)
Status: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
Status: , Estimated PCD: 2026-03-01
Clinical trial
A Phase I/II Study of Zotiraciclib for Recurrent High-Grade Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination With CMP-001 in Patients With Operable Melanoma: Efficacy and Biomarker Study
Status: , Estimated PCD: 2024-12-31
Clinical trial
Phase II Randomized, Double Blind, Placebo-Controlled Trial of Broccoli Seed and Sprout Extract (BSSE), Avmacol ES, to Evaluate Sustained Detoxification of Tobacco Carcinogens in Heavy Smokers
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas
Status: Completed, Estimated PCD: 2023-08-01
Clinical trial
Trastuzumab and Pertuzumab (HP) in Patients With Non-Breast, Non-Gastric/GEJ, and Non-Colorectal Cancers With HER2 Amplification
Status: Active (not recruiting), Estimated PCD: 2024-06-24
Clinical trial
Phase II Study of Azacitidine and Entinostat (SNDX-275) in Patients With Advanced Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2014-03-27
Clinical trial
A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias
Status: Active (not recruiting), Estimated PCD: 2014-03-21
Clinical trial
A Randomized Phase 2 Study of Atezolizumab With or Without Selinexor in Alveolar Soft Part Sarcoma (AXIOM)
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Evaluation of the Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Status: Recruiting, Estimated PCD: 2036-01-30
Clinical trial
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
Status: Recruiting, Estimated PCD: 2030-12-30
Clinical trial
A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)
Status: Completed, Estimated PCD: 2021-05-11
Clinical trial
A Phase I/II Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
Status: Recruiting, Estimated PCD: 2040-06-01
Clinical trial
A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax
Status: Not yet recruiting, Estimated PCD: 2027-12-21
Clinical trial
Phase Ib Trial of Erdafitinib Combined With Enfortumab Vedotin Following Platinum and PD1/L1 Inhibitors for Metastatic Urothelial Carcinoma With FGFR2/3 Genetic Alterations
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Phase 2 Study of Erdafitinib (JNJ-42756493) in Patients With Tumors With FGFR Mutations or Fusions
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas
Status: Completed, Estimated PCD: 2023-06-30
Clinical trial
A Phase 1B Study of AZD9291 in Combination With Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor
Status: Active (not recruiting), Estimated PCD: 2024-07-30
Clinical trial
A Phase I Clinical Trial of T Cells Expressing a Novel Fully-human Anti-BCMA CAR for Treating Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2023-01-01
Clinical trial
A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination With Azacitidine in Patients With 11q23-Rearranged Acute Myeloid Leukemia
Status: Completed, Estimated PCD: 2020-12-08
Clinical trial
A Phase 1 Study of ZEN003694 in Combination With Binimetinib in Solid Tumors With RAS Pathway Alterations and Triple Negative Breast Cancer
Status: Recruiting, Estimated PCD: 2025-03-14
Clinical trial
Phase I Study of MLN0128 (TAK-228) (NSC# 768435) in Combination With Ziv-Aflibercept (NSC# 724770) in Patients With Advanced Cancers
Status: Completed, Estimated PCD: 2021-06-29
Clinical trial
M4OC-Prevent: Metformin for Oral Cancer Prevention
Status: Active (not recruiting), Estimated PCD: 2017-10-12
Clinical trial
A Phase 1 Study of Lenalidomide and Ibrutinib in Combination With Rituximab in Relapsed and Refractory CLL and SLL
Status: Active (not recruiting), Estimated PCD: 2017-03-27
Clinical trial
A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer
Status: Terminated, Estimated PCD: 2021-07-31
Clinical trial
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab
Status: Completed, Estimated PCD: 2021-09-30
Clinical trial
A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination With Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Pilot Study of CBX-12 Pharmacodynamics in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-10-15
Clinical trial
A Phase II Sequential Window of Opportunity Trial of Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 2 Study Using Chemoimmunotherapy With Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC)
Status: Recruiting, Estimated PCD: 2026-08-31
Clinical trial
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)
Status: Active (not recruiting), Estimated PCD: 2022-02-28
Clinical trial
A Phase 1/2 Study of the Bromodomain Inhibitor ZEN003694 in Combination With Etoposide/Platinum in Patients With NUT Carcinoma
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase 1/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2020-03-17
Clinical trial
Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma
Status: Completed, Estimated PCD: 2019-04-01
Clinical trial
A Phase II Study of Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
Status: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer With Neuroendocrine Differentiation
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination With Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Status: Completed, Estimated PCD: 2022-08-15
Clinical trial
A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2019-09-12
Clinical trial
A Feasibility Trial of Alternating Intravaginal Application of 5-Fluorouracil and Imiquimod for Treatment of High-Grade Cervical Squamous Intraepithelial Lesions
Status: Active (not recruiting), Estimated PCD: 2020-11-04
Clinical trial
Liposomal Doxorubicin Versus Carboplatin/Paclitaxel in Patients With Ovarian Cancer Recurrence Between 6 and 12 Months After Previous Platinum Based Therapy: Phase III Randomized Multicenter Study Amendment Title Protocol Version 2.0: Phase III International Multicenter Randomized Study Testing the Effect on Survival of Prolonging Platinum-free Interval in Patients With Ovarian Cancer Recurring Between 6 and 12 Months After Previous Platinum Based Chemotherapy.
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation
Status: Active (not recruiting), Estimated PCD: 2019-06-18
Clinical trial
Phase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination With the Histone Deacetylase Inhibitor Entinostat in Patients With Metastatic Renal Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2019-05-22
Clinical trial
An Open Label, Randomized Phase II Study Neoadjuvant Erdafitinib With or Without Atezolizumab in Cisplatin-Ineligible Patients With Muscle Invasive Bladder Cancer (NERA)
Status: Withdrawn, Estimated PCD: 2023-11-03
Clinical trial
An Open-Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Status: Terminated, Estimated PCD: 2023-08-15
Clinical trial
A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults With Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial
Status: Not yet recruiting, Estimated PCD: 2025-10-31
Clinical trial
A Pilot Study of Tazemetostat and Pembrolizumab (MK-3475) in Advanced Urothelial Carcinoma
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients With Tumors Wtih mTOR Mutations
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase 1 Study of Talazoparib (BMN 673) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2019-04-01
Clinical trial
A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients With Pancreas Adenocarcinoma and a Known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma (Part II)
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Status: Active (not recruiting), Estimated PCD: 2023-09-30
Clinical trial
A Phase 1 Study of Blinatumomab in Combination With Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients With Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
Status: Active (not recruiting), Estimated PCD: 2023-05-22
Clinical trial
A Phase 1b Trial of ZEN003694 (ZEN-3694) With Pembrolizumab and Nab-Paclitaxel in Patients With Metastatic Triple-Negative Breast Cancer
Status: , Estimated PCD: 2025-12-31
Clinical trial
A Phase II Trial of the Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)
Status: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Phase Ib Clinical Trial to Evaluate the Administration of Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
Status: Recruiting, Estimated PCD: 2031-06-15
Clinical trial
Preclinical and Clinical Study of Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
Status: Active (not recruiting), Estimated PCD: 2019-04-11
Clinical trial
A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination With the ATR Inhibitor M1774
Status: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
A Phase I/II Biomarker Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Pilot Study of Sorafenib in Patients With Acute Myeloid Leukemia as Peri-Transplant Remission Maintenance
Status: Completed, Estimated PCD: 2020-10-28
Clinical trial
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies
Status: , Estimated PCD: 2035-10-01
Clinical trial
A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial
Status: Recruiting, Estimated PCD: 2028-10-01
Clinical trial
A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Phase II Trial of MK-3475 (Pembrolizumab) and Interferon Gamma 1-b Combination Immunotherapy in Patients With Previously Treated Mycosis Fungoides and Sezary Syndrome (Treatment Group 1) and in Patients With Advanced Synovial Sarcoma (Treatment Group 2)
Status: Completed, Estimated PCD: 2021-04-08
Clinical trial
Phase I Trial of BAY 1895344 ATR Inhibitor Combined With Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2024-11-27
Clinical trial
MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients With Tumors With CCND1, 2, 3 Amplification
Status: Active (not recruiting), Estimated PCD: 2021-03-09
Clinical trial
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Status: Active (not recruiting), Estimated PCD: 2018-03-02
Clinical trial
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
Status: Active (not recruiting), Estimated PCD: 2023-09-19
Clinical trial
Pilot Study of MLN0128 (TAK-228) in Preoperative Recurrent Glioblastoma (GBM) Patients
Status: Terminated, Estimated PCD: 2020-01-31
Clinical trial
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
Autophagic Modulation With Anti-angiogenic Therapy in Patients With Advanced Malignancies: A Phase I Trial of Sunitinib and Hydroxychloroquine
Status: Completed, Estimated PCD: 2023-07-18
Clinical trial
A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
MATCH Treatment Subprotocol I: GDC-0032 (Taselisib) in Patients With Tumors (Other Than Breast Cancer) With PIK3CA Mutation But Without KRAS Mutation or PTEN Loss
Status: Active (not recruiting), Estimated PCD: 2020-11-10
Clinical trial
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Status: , Estimated PCD: 2025-05-31
Clinical trial
MATCH Treatment Subprotocol Z1F: Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations (PTEN Loss Allowed)
Status: Active (not recruiting), Estimated PCD: 2021-01-06
Clinical trial
A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Status: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients With Relapsed Osteosarcomas and Ewing Sarcomas
Status: Active (not recruiting), Estimated PCD: 2019-06-30
Clinical trial
Phase I Trial of Oral 5-Fluoro-2'-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2019-10-07
Clinical trial
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Active (not recruiting), Estimated PCD: 2018-07-17
Clinical trial
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Status: , Estimated PCD: 2030-03-20
Clinical trial
A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients
Status: Not yet recruiting, Estimated PCD: 2024-05-31
Clinical trial
Phase II Study of Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in Patients With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
Status: Completed, Estimated PCD: 2022-10-31
Clinical trial
Endocrine Therapy With or Without Anti-VEGF Therapy: A Randomized, Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865) for Women With Hormone Receptor-Positive Advanced Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2014-06-30
Clinical trial
A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, Dinutuximab) (NSC# 764038) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma
Status: Active (not recruiting), Estimated PCD: 2021-12-31
Clinical trial
MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients With Tumors With cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuorendocrine Tumor)
Status: Active (not recruiting), Estimated PCD: 2025-03-24
Clinical trial
Molecular Analysis for Therapy Choice (MATCH)
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
Neoadjuvant Androgen Deprivation and Enzalutamide: Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2019-12-01
Clinical trial
Phase I Trial of TURALIO (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCT)
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active (not recruiting), Estimated PCD: 2020-02-23
Clinical trial
A Randomized Trial of Apalutamide in Non-Muscle Invasive Bladder Cancer
Status: Not yet recruiting, Estimated PCD: 2026-11-15
Clinical trial
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2014-08-01
Clinical trial
A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
Status: Active (not recruiting), Estimated PCD: 2021-02-01
Clinical trial
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
Status: Active (not recruiting), Estimated PCD: 2021-10-15
Clinical trial
Phase I/II Study of NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients With Tumors With FGFR Amplifications
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Status: Active (not recruiting), Estimated PCD: 2018-05-16
Clinical trial
A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination With Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
Phase 2 Study of Low Dose Tamoxifen +/- High Dose Omega-3 Fatty Acids in Overweight Postmenopausal Women at Increased Risk for Breast Cancer
Status: Not yet recruiting, Estimated PCD: 2027-01-01
Clinical trial
A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
Status: , Estimated PCD: 2024-11-30
Clinical trial
Randomized Phase 2 Study of Nivolumab and Ipilimumab With or Without Cabozantinib in Patients With Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy
Status: Recruiting, Estimated PCD: 2028-06-16
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations
Status: Active (not recruiting), Estimated PCD: 2023-09-30
Clinical trial
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement
Status: Active (not recruiting), Estimated PCD: 2020-09-30
Clinical trial
Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis
Status: Completed, Estimated PCD: 2018-12-30
Clinical trial
MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients With Tumors With CDK4 or CDK6 Amplification
Status: Active (not recruiting), Estimated PCD: 2025-03-24
Clinical trial
MATCH Treatment Subprotocol U: VS-6063 (Defactinib) in Patients With Tumors With NF2 Loss
Status: Active (not recruiting), Estimated PCD: 2025-05-31
Clinical trial
A Phase I Study of Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
Status: Completed, Estimated PCD: 2020-12-01
Clinical trial
A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)
Status: Completed, Estimated PCD: 2018-02-06
Clinical trial
A Phase 1 Study of MLN7243 (TAK-243) for Either Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia Refractory to Hypomethylating Agents
Status: Not yet recruiting, Estimated PCD: 2024-12-11
Clinical trial
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Phase II Trial of Lenalidomide (Revlimid (TM), CC-5013) (NSC #703813) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL)
Status: Completed, Estimated PCD: 2012-12-31
Clinical trial
BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)
Status: Active (not recruiting), Estimated PCD: 2025-02-15
Clinical trial
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Status: Completed, Estimated PCD: 2020-04-21
Clinical trial
Alternative Dosing of Exemestane in Postmenopausal Women With Stage 0-II ER-Positive Breast Cancer: A Randomized Presurgical Trial
Status: Completed, Estimated PCD: 2019-10-03
Clinical trial
A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2024-10-21
Clinical trial
A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and Durvalumab (MEDI4736) in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Status: Active (not recruiting), Estimated PCD: 2022-09-20
Clinical trial
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Status: Active (not recruiting), Estimated PCD: 2028-04-01
Clinical trial
A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase Ib Trial of Concurrent Cetuximab (ERBITUX®) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY®) in Locally Advanced Head and Neck Cancer
Status: Completed, Estimated PCD: 2016-10-29
Clinical trial
Phase I/II Study of Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Phase 1b Study With Expansion Cohort of Escalating Doses of KRT-232 (AMG 232) Administered in Combination With Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed Acute Myelogenous Leukemia (AML)
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
Clinical Study of Avmacol® for Detoxification of Tobacco Carcinogens in Heavy Smokers
Status: Completed, Estimated PCD: 2020-01-10
Clinical trial
MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients With Tumors With PTEN Loss by IHC and Any PTEN Sequencing Result
Status: Active (not recruiting), Estimated PCD: 2024-11-15
Clinical trial
MATCH Treatment Subprotocol C1: Crizotinib in Patients With Tumors With MET Amplification
Status: Active (not recruiting), Estimated PCD: 2024-11-15
Clinical trial
MATCH Treatment Subprotocol C2: Crizotinib in Patients With Tumors With MET Exon 14 Deletion
Status: Active (not recruiting), Estimated PCD: 2024-11-15
Clinical trial
MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E or V600K Mutations (Excluding Melanoma, Thyroid Cancer, Colorectal Adenocarcinoma, and Non-Small Cell Lung Cancer)
Status: Active (not recruiting), Estimated PCD: 2025-04-02
Clinical trial
A Randomized Phase II Trial of MLN4924 (Pevonedistat) With Azacitidine Versus Azacitidine in Adult Relapsed or Refractory Acute Myeloid Leukemia
Status: Withdrawn, Estimated PCD: 2021-08-19
Clinical trial
A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
Status: Active (not recruiting), Estimated PCD: 2025-09-01
Clinical trial
A Phase Ib/II Study of AZD2171 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma Not Taking Enzyme-Inducing Anti-epileptic Drugs
Status: Completed, Estimated PCD: 2014-04-01
Clinical trial
Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy
Status: Active (not recruiting), Estimated PCD: 2024-10-31
Clinical trial
A Phase 1/Randomized Phase 2 Study of M3814 (Peposertib) in Combination With Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, Esophageal Carcinomas, or Pleural Mesotheliomas
Status: Terminated, Estimated PCD: 2021-10-06
Clinical trial
A Phase 1 Study of Dabrafenib in Combination With Lapatinib in BRAF Mutant Thyroid Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Randomized Phase 1/2 Trial Evaluating the Addition of Tolinapant to Weekly Paclitaxel With or Without Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer
Status: Not yet recruiting, Estimated PCD: 2028-02-09
Clinical trial
Immune Checkpoint Blockade for Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
Status: Active (not recruiting), Estimated PCD: 2022-10-11
Clinical trial
A Phase I/Ib Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination With Olaparib in Patients With BRCA1/2-Mutant Tumors
Status: Withdrawn, Estimated PCD: 2026-12-06
Clinical trial
Non-Inferiority Trial Comparing Immunogenicity From 1-Dose of Bivalent HPV Vaccine in Girls to 3-Doses of Quadrivalent Vaccine in Women: The PRIMAVERA-ESCUDDO Trial ("Puente de Respuesta Inmunológica Para Mejorar el Acceso a Vacunas y ERrAdicar el Cancer")
Status: Active (not recruiting), Estimated PCD: 2022-09-30
Clinical trial
MATCH Treatment Subprotocol Z1K: Ipatasertib in Patients With Tumors With AKT Mutations
Status: Active (not recruiting), Estimated PCD: 2025-03-03
Clinical trial
A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers With Response and Resistance
Status: Active (not recruiting), Estimated PCD: 2018-02-10
Clinical trial
A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
Status: Active (not recruiting), Estimated PCD: 2023-08-27
Clinical trial
A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2015-01-31
Clinical trial
A Phase II Trial of DCTD-Sponsored Dasatinib in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression
Status: Terminated, Estimated PCD: 2017-02-06
Clinical trial
A Phase II Basket Trial of Glutaminase Inhibitor (BEGIN) Telaglenastat (CB-839) HCL in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors
Status: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
Phase II Study of Dose-Adjusted EPOCH+/-Rituximab in Adults With Untreated Burkitt Lymphoma, c-MYC Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma
Status: Completed, Estimated PCD: 2020-09-30
Clinical trial
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors
Status: Completed, Estimated PCD: 2017-12-18
Clinical trial
A Phase II Study Using the Administration of Autologous T-Cells Engineered Using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients With Metastatic Cancer
Status: Withdrawn, Estimated PCD: 2024-03-08
Clinical trial
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
Status: Active (not recruiting), Estimated PCD: 2019-04-04
Clinical trial
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Status: Active (not recruiting), Estimated PCD: 2022-02-16
Clinical trial
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Active (not recruiting), Estimated PCD: 2019-03-05
Clinical trial
A Phase 0/I/II Study of the Cyclin-Dependent Kinase(CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type 1 (NF1) Related Atypical Neurofibromas
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Status: , Estimated PCD: 2025-02-28
Clinical trial
Phase II Trial of Oral Iloprost for the Precision Chemoprevention of Lung Cancer
Status: Withdrawn, Estimated PCD: 2026-12-01
Clinical trial
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Status: Active (not recruiting), Estimated PCD: 2023-01-26
Clinical trial
Phase I/II Trial of Systemic Targeted Radioligand Therapy (TRT) With Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR Positive (SSTR+) Gastrointestinal (GI) Neuroendocrine Tumors (NET) and Pheochromocytoma/Paragangliomas Previously Treated With Systemic Radioligand Therapy
Status: Not yet recruiting, Estimated PCD: 2029-07-01
Clinical trial
Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma: Phase III Study
Status: Completed, Estimated PCD: 2011-02-01
Clinical trial
A Phase IIb Study of Molecular Responses to Imatinib, at Standard or Increased Doses, or Dasatinib (BMS-354825) (NSC-732517) for Previously Untreated Patients With Chronic Myelogenous Leukemia (CML) in Chronic Phase
Status: Active (not recruiting), Estimated PCD: 2010-11-01
Clinical trial
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2023-12-10
Clinical trial
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Active (not recruiting), Estimated PCD: 2019-05-26
Clinical trial
A Phase 1 Study of Pembrolizumab (MK-3475) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC
Status: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination With Fulvestrant in Patients With Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor
Status: Withdrawn, Estimated PCD: 2022-02-19
Clinical trial
A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Completed, Estimated PCD: 2021-09-30
Clinical trial
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
Status: , Estimated PCD: 2028-06-30
Clinical trial
Randomized Phase 2 Study of Daunorubicin and Cytarabine Liposome + Pomalidomide Versus Daunorubicin and Cytarabine Liposome in Newly Diagnosed AML With MDS-Related Changes
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib Plus Cabozantinib as 2nd or 3rd Line Therapy in Patients With EGFR Wild-Type NSCLC
Status: Active (not recruiting), Estimated PCD: 2015-08-14
Clinical trial
A Phase 1/1a Study of Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2020-11-06
Clinical trial
A Phase 1b/2 Study of Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase II Study of Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma and Multicentric Castleman Disease
Status: Recruiting, Estimated PCD: 2034-08-01
Clinical trial
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors
Status: , Estimated PCD: 2027-05-28
Clinical trial
A Pilot Study to Evaluate the Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic Cancer
Status: Recruiting, Estimated PCD: 2027-03-23
Clinical trial
A Phase I Trial of 5Azacitidine and Suberoylanilide Hydroxamic Acid in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma and Nasal NK-T Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2013-04-19
Clinical trial
A Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)
Status: Recruiting, Estimated PCD: 2028-10-01
Clinical trial
A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients With Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated With Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation
Status: Active (not recruiting), Estimated PCD: 2016-10-31
Clinical trial
Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
A Phase II Study of Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
Status: Active (not recruiting), Estimated PCD: 2023-02-25
Clinical trial
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD
Status: Active (not recruiting), Estimated PCD: 2019-03-31
Clinical trial
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2022-06-07
Clinical trial
A Phase 1 Study of Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-03-29
Clinical trial
MATCH Treatment Subprotocol T: GDC-0449 (Vismodegib) in Patients With Tumors (Except Basal Cell Skin Carcinoma) With Smoothened (SMO) or Patched 1 (PTCH1) Mutations
Status: Active (not recruiting), Estimated PCD: 2024-11-04
Clinical trial
Phase 1 Trial of Gemcitabine Combined With the Elimusertib (BAY 1895344) ATR Inhibitor With Expansion Cohorts in Advanced Pancreatic and Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation
Status: Completed, Estimated PCD: 2024-03-08
Clinical trial
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Status: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)
Status: Active (not recruiting), Estimated PCD: 2015-02-25
Clinical trial
MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (Tak-228) in Patients With Tumors With TSC1 or TSC2 Mutations
Status: Active (not recruiting), Estimated PCD: 2025-01-06
Clinical trial
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm) - IIIA Non-small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2015-10-20
Clinical trial
Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)
Status: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Status: Active (not recruiting), Estimated PCD: 2024-09-15
Clinical trial
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
Status: Active (not recruiting), Estimated PCD: 2021-10-06
Clinical trial
Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecaptagene Vicleucel CAR-T in Multiple Myeloma Patients
Status: Recruiting, Estimated PCD: 2027-10-31
Clinical trial
A Phase 1B Study of KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Acute Myeloid Leukemia
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase 0 Window-of-Opportunity Pharmacodynamic Trial of Triapine (NSC# 663249) in Uterine Corpus Serous Adenocarcinoma
Status: Recruiting, Estimated PCD: 2024-11-10
Clinical trial
A Randomized Phase 2 Study of ATR Inhibition in Advanced PD-(L)1-Refractory Merkel Cell Carcinoma: The MATRiX Trial
Status: Recruiting, Estimated PCD: 2028-01-01
Clinical trial
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Status: Active (not recruiting), Estimated PCD: 2024-10-31
Clinical trial
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Status: Active (not recruiting), Estimated PCD: 2028-12-31
Clinical trial
A Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Status: , Estimated PCD: 2025-12-31
Clinical trial
Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients With Metastatic Esophageal or GE Junction Cancer
Status: Active (not recruiting), Estimated PCD: 2014-07-15
Clinical trial
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2027-04-27
Clinical trial
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Completed, Estimated PCD: 2019-07-03
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
Status: Active (not recruiting), Estimated PCD: 2021-06-30
Clinical trial
Pilot Study of EGFR Inhibition With Erlotinib in Cirrhosis to Inhibit Fibrogenesis and Prevent Hepatocellular Carcinoma
Status: Completed, Estimated PCD: 2020-02-11
Clinical trial
A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
Status: Active (not recruiting), Estimated PCD: 2022-10-01
Clinical trial
A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) After Prior Platinum Containing First-Line Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2019-01-13
Clinical trial
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2022-12-16
Clinical trial
A Phase I and Randomized Phase II Study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in Relapsed, Refractory Diffuse Large-B Cell Lymphoma
Status: Completed, Estimated PCD: 2021-01-06
Clinical trial
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Status: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Completed, Estimated PCD: 2018-02-15
Clinical trial
A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) in Combination With Rituximab-CHOP in Patients With Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Active (not recruiting), Estimated PCD: 2015-12-30
Clinical trial
A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-11-21
Clinical trial
Randomized Phase 2 Study of Valproic Acid combinEd With Simvastatin and Gemcitabine/Nab-paclitaxel-based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients (The VESPA Trial).
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase II Study of Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer
Status: Not yet recruiting, Estimated PCD: 2027-11-01
Clinical trial
T Cells Expressing a Fully-Human Anti-CD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
Status: Completed, Estimated PCD: 2018-06-12
Clinical trial
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
Status: Recruiting, Estimated PCD: 2027-10-31
Clinical trial
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
Status: Recruiting, Estimated PCD: 2028-07-01
Clinical trial
Randomized Phase 3 Study on the Optimization of Bevacizumab With mFOLFOX/mOXXEL in the Treatment of Patients With Metastatic Colorectal Cancer
Status: Completed, Estimated PCD: 2015-12-01
Clinical trial
Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
Status: Active (not recruiting), Estimated PCD: 2020-11-30
Clinical trial
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Status: Active (not recruiting), Estimated PCD: 2015-06-01
Clinical trial
A Phase II Trial of Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study
Status: Recruiting, Estimated PCD: 2023-09-01
Clinical trial
A Randomized Multicenter Phase III Trial Comparing Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Status: Active (not recruiting), Estimated PCD: 2014-02-12
Clinical trial
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Status: Active (not recruiting), Estimated PCD: 2027-06-01
Clinical trial
Phase I Trial of the Combination of Vismodegib GDC-0449 and Erlotinib +/- Gemcitabine
Status: Active (not recruiting), Estimated PCD: 2013-01-22
Clinical trial
Phase 1/2 Study of Valproic Acid and Short-course Radiotherapy Plus Capecitabine as preoperatIve Treatment in Low-moderate Risk Rectal Cancer
Status: Recruiting, Estimated PCD: 2023-11-01
Clinical trial
Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer, a Phase 2 Study
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Randomized Open-label Phase 3 Trial Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 Pneumonia
Status: Active (not recruiting), Estimated PCD: 2023-12-19
Clinical trial
GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Osteosarcoma or Neuroblastoma to Increase Systemic Tumor Exposure
Status: , Estimated PCD: 2040-12-31
Clinical trial
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer
Status: Recruiting, Estimated PCD: 2034-12-30
Clinical trial
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Phase 1 Study of Mosunetuzumab With Polatuzumab Vedotin and Lenalidomide (M+Pola+Len) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Recruiting, Estimated PCD: 2026-06-29
Clinical trial
Phase III Randomized Study of the Effects on Bone Mineral Density of Tamoxifen, Letrozole, and Letrozole + Zoledronic Acid as Adjuvant Treatment of Patients With Early Breast Cancer; VERSION 2 AMENDED Phase 3 Study of Triptorelin and Tamoxifen, Letrozole, or Letrozole + Zoledronic Acid in Adjuvant Treatment of Premenopausal Endocrine Responsive Breast Cancer Patients.
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
A MULTICENTER STUDY IN PATIENTS WITH STAGE III-IV EPITHELIAL OVARIAN CANCER TREATED WITH CARBOPLATIN/PACLITAXEL WITH BEVACIZUMAB: CLINICAL AND BIOLOGICAL PROGNOSTIC FACTORS
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
MITO 35a: A Multicenter, Prospective, Single Arm Trial of Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wildtype Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Phase II Placebo-Controlled Trial of Urolithin a Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy
Status: Not yet recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Phase I Study of M6620 (VX-970, Berzosertib) in Combination With Cisplatin and XRT in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A Phase II Study of Dasatinib (Sprycel&#174;) (NSC #732517) as Primary Therapy Followed by Transplantation for Adults &gt;/= 18 Years With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG
Status: Completed, Estimated PCD: 2017-11-14
Clinical trial
Randomized Phase III Study of the Addition of Cisplatin in Combination With Gemcitabine as First-line Therapy for Elderly Patients With Advanced Non Small Cell Lung Cancer.
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
PRECOL2011-1: Sodium Picophosphate and Magnesium Citrate Versus Polyethylene Glycol as Evacuating Treatment Prior to Colonoscopy: Phase IV Randomized Trial.
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Comparative Study of Pediatric CNS Tumor Activity as Assessed by 18F-FDG PET Imaging and Proton Magnetic Resonance Spectroscopic Imaging (1H-MRSI)
Status: Completed, Estimated PCD: 2019-05-10
Clinical trial
Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Cetuximab, Irinotecan and Fluorouracile in fiRst-line Treatment of Immunologically-selected Advanced Colorectal Cancer Patients: the CIFRA Study
Status: Recruiting, Estimated PCD: 2023-05-19
Clinical trial
Phase IIB Randomized, Placebo-Controlled Trial of ACTOplus Met® XR in Subjects With Stage I-IV Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Prior to Definitive Treatment
Status: Terminated, Estimated PCD: 2019-08-28
Clinical trial
A Factorial Study Comparing Pemetrexed With Gemcitabine and Testing the Efficacy of the Addition of Cisplatin in Elderly Patients With Non Squamous Advanced, Metastatic or Recurrent NSCLC.
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. The Phase III Randomized, Open Label MITO 35b Study: a Project of the MITO-MANGO Groups.
Status: Recruiting, Estimated PCD: 2028-01-21
Clinical trial
Multicentered Phase II Study Evaluating the Activity and Toxicity of Liposomal Cytarabine in the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia With Resistent or Relapsed Central Nervous System Involvement
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Weekly Versus Every 3 Week Carboplatin and Paclitaxel in Patients With Ovarian Cancer: a Phase III Randomized Multicenter Study
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Completed, Estimated PCD: 2020-10-01
Clinical trial
A Genetic Risk-Stratified, Randomized Phase II Study of Four Fludarabine/Antibody Combinations for Patients With Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia
Status: Completed, Estimated PCD: 2014-12-01
Clinical trial
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
Status: Completed, Estimated PCD: 2022-05-27
Clinical trial
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
Status: Recruiting, Estimated PCD: 2026-05-31
Clinical trial
Phase II Trial of Raf Kinase Inhibitor BAY 43-9006 as Single Oral Agent in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane
Status: , Estimated PCD: 2006-06-01
Clinical trial
A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
Status: , Estimated PCD: 2026-12-31
Clinical trial
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Phase II Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy Plus Dasatinib (NSC #732517) and Continuation Therapy With Dasatinib Alone in Newly Diagnosed Patients With Core Binding Factor Acute Myeloid Leukemia (AML)
Status: Completed, Estimated PCD: 2013-07-01
Clinical trial
Phase II Trial of VEGF Trap in Patients With Previously Treated Metastatic Colorectal Cancer
Status: Completed, Estimated PCD: 2012-09-01
Clinical trial
A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2023-06-30
Clinical trial
A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients With Advanced Pancreatic Carcinoma
Status: Active (not recruiting), Estimated PCD: 2017-09-06
Clinical trial
Phase I and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2'- Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Gastrointestinal Cancers
Status: Active (not recruiting), Estimated PCD: 2018-11-08
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations
Status: Active (not recruiting), Estimated PCD: 2024-03-31
Clinical trial
Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
Status: , Estimated PCD: 2025-12-31
Clinical trial
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Status: Recruiting, Estimated PCD: 2033-06-30
Clinical trial
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Status: Active (not recruiting), Estimated PCD: 2025-04-02
Clinical trial
A Phase II Trial of Durvalumab With Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma
Status: Recruiting, Estimated PCD: 2026-02-12
Clinical trial
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: , Estimated PCD: 2025-03-20
Clinical trial
A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
Status: Active (not recruiting), Estimated PCD: 2018-06-05
Clinical trial
Phase II Trial of Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology
Status: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
Status: Active (not recruiting), Estimated PCD: 2018-09-30
Clinical trial
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Phase I Study of the Combination of the VEGFR Inhibitor, AZD2171, and MEK Inhibitor, AZD6244, in the Treatment of Solid Malignancies
Status: Active (not recruiting), Estimated PCD: 2019-06-06
Clinical trial
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma
Status: Completed, Estimated PCD: 2016-11-12
Clinical trial
A Phase I Trial of MK-2206 and Hydroxychloroquine in Solid Tumors, Melanoma, Renal and Prostate Cancer to Examine the Role of Autophagy in Tumorigenesis
Status: Active (not recruiting), Estimated PCD: 2020-02-14
Clinical trial
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients With PD-L1 CPS &gt;/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMMUNE)
Status: Recruiting, Estimated PCD: 2027-10-31
Clinical trial
A Phase IB and Randomized Phase II Trial of Megestrol Acetate With or Without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer
Status: Recruiting, Estimated PCD: 2027-01-31
Clinical trial
A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients With Refractory/Recurrent Neuroblastoma
Status: Active (not recruiting), Estimated PCD: 2018-09-14
Clinical trial
Single-Dose HPV Vaccination Among Young Adult Women in Costa Rica: the PRISMA-ESCUDDO Trial (PRevencIón Del Cáncer Cervical Con Una Sola Dosis de Vacuna Contra VPH en Mujeres Adultas Jóvenes)
Status: Active (not recruiting), Estimated PCD: 2026-05-31
Clinical trial
A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination With Copanlisib in Patients With Metastatic Triple Negative Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
Status: Active (not recruiting), Estimated PCD: 2024-12-05
Clinical trial
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Status: Active (not recruiting), Estimated PCD: 2019-05-15
Clinical trial
A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
Status: Active (not recruiting), Estimated PCD: 2022-02-03
Clinical trial
A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Status: Completed, Estimated PCD: 2020-07-29
Clinical trial
Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase II Single Arm Interventional Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Randomized Phase II Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
Status: Not yet recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Status: Active (not recruiting), Estimated PCD: 2027-09-30
Clinical trial
A Phase 1 Study of Trametinib in Combination With Chemoradiation for KRAS Mutant Non-small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2017-11-03
Clinical trial
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Status: Active (not recruiting), Estimated PCD: 2023-05-24
Clinical trial
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Randomized Phase II Trial of Adjuvant Nivolumab With or Without Cabozantinib in Patients With Resected Mucosal Melanoma
Status: Recruiting, Estimated PCD: 2024-12-19
Clinical trial
Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
Status: Completed, Estimated PCD: 2016-08-15
Clinical trial
A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
Phase II Study of gp100:209-217 (210M) Antigen and MART-1:26-35 (27L) Antigen Emulsified in Montanide ISA-51 in Patients With Metastatic Ocular Melanoma
Status: Completed
Clinical trial
A Phase 2 Study of Ipatasertib in Combination With Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma
Status: Active (not recruiting), Estimated PCD: 2017-08-08
Clinical trial
A Phase II Clinical Trial of Pembrolizumab in Combination With Carboplatin-paclitaxel in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer: MITO28/MANGO OV4 Study
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients With ROS1 Translocations (Other Than Patients With Non-Small Cell Lung Cancer)
Status: Active (not recruiting), Estimated PCD: 2020-03-20
Clinical trial
MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients With Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
Status: Active (not recruiting), Estimated PCD: 2024-12-06
Clinical trial
A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2014-01-07
Clinical trial
Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active (not recruiting), Estimated PCD: 2018-09-05
Clinical trial
A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined With Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer
Status: Not yet recruiting, Estimated PCD: 2026-01-31
Clinical trial
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age &gt;/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-03-31
Clinical trial
Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Status: Active (not recruiting), Estimated PCD: 2020-06-30
Clinical trial
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
Status: Recruiting, Estimated PCD: 2027-06-01
Clinical trial
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Status: Active (not recruiting), Estimated PCD: 2018-07-17
Clinical trial
Phase II Study of Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
Status: Terminated, Estimated PCD: 2022-05-11
Clinical trial
A Phase I Study of MLN8237 in Combination With Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma
Status: Active (not recruiting), Estimated PCD: 2018-05-29
Clinical trial
Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: a Clinical and Correlative Pilot Study
Status: Active (not recruiting), Estimated PCD: 2022-03-03
Clinical trial
Phase 0/I Study of AMG 232 (KRT 232) Concentrations in Brain Tissue in Patients With Recurrent Glioblastoma and of AMG 232 (KRT 232) in Combination With Radiation in Patients With Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Study of the Role of Metabolic Response Measured by PET/CT Scan After 1 Cycle of First-line Therapy in Patients With Advanced Colorectal Cancer (CRC)
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Randomized Phase 2 Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Phase I and Randomized Phase II Study of Nab-Paclitaxel/Gemcitabine With or Without AZD1775 for Treatment of Metastatic Adenocarcinoma of the Pancreas
Status: Completed, Estimated PCD: 2021-06-03
Clinical trial
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Status: Completed, Estimated PCD: 2021-02-17
Clinical trial
Combination Chemotherapy With or Without Maintenance Sunitinib Malate (NSC 736511) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/Randomized Phase II Study
Status: Completed, Estimated PCD: 2013-06-30
Clinical trial
Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
Status: Recruiting, Estimated PCD: 2025-08-20
Clinical trial
Phase II Trial of M7824 in Subjects With HPV Associated Malignancies
Status: Completed, Estimated PCD: 2021-02-02
Clinical trial
Phase 1/2 Study of Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2026-02-28
Clinical trial
A Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury) Vaccine (TRI-AD5) and IL-15 Superagonist N-803 in Lynch Syndrome
Status: Recruiting, Estimated PCD: 2027-02-01
Clinical trial
Multicenter Randomized Phase III Study Comparing Fixed Doses Versus Toxicity Adjusted Dosing of Cisplatin and Etoposide for Patients With Small Cell Lung Cancer.
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer: a Multicentre, Single-arm, Two-stage, Phase 2 Study
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
Phase II Study of Intrathecal Ziconotide for the Treatment of Neuropathic Pain in Patients With Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
Status: Active (not recruiting), Estimated PCD: 2021-07-21
Clinical trial
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Active (not recruiting), Estimated PCD: 2028-05-07
Clinical trial
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With &gt;/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2026-05-31
Clinical trial
A Phase 2 Study of Venetoclax in Relapsed Classic or Variant Hairy Cell Leukemia
Status: Recruiting, Estimated PCD: 2027-05-20
Clinical trial
Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients
Status: Active (not recruiting), Estimated PCD: 2015-01-01
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex
Status: Active (not recruiting), Estimated PCD: 2022-03-31
Clinical trial
[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients With Newly Diagnosed Metastatic Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2025-04-04
Clinical trial
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Active (not recruiting), Estimated PCD: 2021-12-01
Clinical trial
Pilot Study of Daily Exemestane in Women With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2023-12-13
Clinical trial
A Randomized Phase II Trial of Decitabine-Based Induction Strategies for Patients &gt;/= 60 Years Old With Acute Myeloid Leukemia (AML)
Status: Completed, Estimated PCD: 2016-06-05
Clinical trial
Phase 1 Trial of Hu5F9-G4 (Magrolimab) Combined With Dinutuximab in Children and Young Adults With Relapsed and Refractory Neuroblastoma or Relapsed Osteosarcoma
Status: Active (not recruiting), Estimated PCD: 2032-12-31
Clinical trial
Phase I Trial of ZEN003694 (ZEN-3694) in Combination With Capecitabine in Patients With Solid Tumors
Status: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Status: Active (not recruiting), Estimated PCD: 2023-08-23
Clinical trial
Vorinostat and Carboplatin or Vorinostat and Paclitaxel in Patients With Advanced Solid Tumors: A Pharmacokinetic and Pharmacodynamic Study
Status: Active (not recruiting), Estimated PCD: 2014-04-30
Clinical trial
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
Status: Completed, Estimated PCD: 2021-12-17
Clinical trial
Pilot Study of Idiotype Vaccine and EPOCH-Rituximab Chemotherapy in Untreated Mantle Cell Lymphoma
Status: Completed, Estimated PCD: 2021-06-09
Clinical trial
A Phase 1b Study of Berzosertib in Combination With Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2024-11-20
Clinical trial
MATCH Treatment Subprotocol N: Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients With Tumors With PTEN Mutation or Deletion, With PTEN Expression on IHC
Status: Active (not recruiting), Estimated PCD: 2024-11-30
Clinical trial
A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Pilot Study of GCC Agonists to Identify a Cyclic-GMP Signal in Duodenal Tissue of Volunteers
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to Patients With CD70-Expressing Cancers
Status: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
A Phase 1 Trial of MLN0128 (TAK-228) in Combination With Osimertinib (AZD9291) in Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Status: Active (not recruiting), Estimated PCD: 2024-06-29
Clinical trial
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
Status: Active (not recruiting), Estimated PCD: 2023-04-21
Clinical trial
Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma
Status: Active (not recruiting), Estimated PCD: 2017-09-30
Clinical trial
A Phase 2 Study of Acalabrutinib With DA-EPOCH-R or R-CHOP for Patients With Untreated Diffuse Large B-cell Lymphoma
Status: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
Phase I/II Trial to Determine the Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Status: Recruiting, Estimated PCD: 2027-06-25
Clinical trial
A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-10-31
Clinical trial
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Status: Recruiting, Estimated PCD: 2024-11-02
Clinical trial
A Randomized Phase III Study of CC-5013 Plus Dexamethasone Versus CC-5013 Plus Low Dose Dexamethasone in Multiple Myeloma With Thalidomide Plus Dexamethasone Salvage Therapy for Non-Responders
Status: Active (not recruiting), Estimated PCD: 2008-11-30
Clinical trial
NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus in Metastatic/Unresectable Midgut NET
Status: Recruiting, Estimated PCD: 2026-04-30
Clinical trial
A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human Interleukin IL-15 (rhIL-15) in Adults With Metastatic Cancers
Status: Completed, Estimated PCD: 2019-06-20
Clinical trial
MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-10
Clinical trial
Phase II Study of Autologous Myeloma-Derived Immunoglobulin Idiotype Conjugated to Keyhole Limpet Hemocyanin Plus Sargramostim (GM-CSF) in Patients With Multiple Myeloma Undergoing Second Autologous Peripheral Blood Stem Cell Transplantation
Status: Completed
Clinical trial
Phase I/II Pilot Study of Interleukin-12 in Patients With AIDS-Associated Kaposi's Sarcoma
Status: Completed
Clinical trial
A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment With Osimertinib (AZD9291, Tagrisso)
Status: Completed, Estimated PCD: 2022-05-25
Clinical trial
A Phase 1 Trial of Pomalidomide in Combination With Liposomal Doxorubicin in Patients With Advanced or Refractory Kaposi Sarcoma
Status: Active (not recruiting), Estimated PCD: 2026-01-01
Clinical trial
A Phase I Study of Talimogene Laherparepvec (Talimogene Laherparepvec) With Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum
Status: Terminated, Estimated PCD: 2022-03-22
Clinical trial
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction
Status: Active (not recruiting), Estimated PCD: 2018-11-29
Clinical trial
Phase I Study of BMS-247550 in Patients With Refractory Neoplasms
Status:
Clinical trial
Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease Activity
Status: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
Phase I and Dose-Expansion Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
Status: Recruiting, Estimated PCD: 2025-06-20
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations
Status: Active (not recruiting), Estimated PCD: 2022-06-30
Clinical trial
A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1) in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatments
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Immunotherapy for Unresectable Pancreas Cancer: A Phase 1 Study of Intratumoral Recombinant Fowlpox PANVAC (PANVAC-F) Plus Subcutaneous Recombinant Vaccinia PANVAC (PANVAC-V), PANVAC-F and Recombinant Granulocyte-Macrophage Colony Stimulating Factor (rH-GM-CSF)
Status: Active (not recruiting), Estimated PCD: 2021-09-02
Clinical trial
Phase II Randomized, Placebo-Controlled Trial of PROSTVAC (PSA-TRICOM) in Patients With Clinically Localized Prostate Cancer Undergoing Active Surveillance
Status: Completed, Estimated PCD: 2018-11-30
Clinical trial
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Status: Active (not recruiting), Estimated PCD: 2025-11-30
Clinical trial
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Status: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients With Previously Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant
Status: Active (not recruiting), Estimated PCD: 2016-07-01
Clinical trial
A Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in Combination With Temozolomide in Patients With Malignant Gliomas
Status: Active (not recruiting), Estimated PCD: 2018-10-18
Clinical trial
A Phase III Study of Daunorubicin and Cytarabine +/- G3139 (Genasense, Oblimersen Sodium, NSC #683428, IND #58842), a BCL2 Antisense Oligodeoxynucleotide, in Previously Untreated Patients With Acute Myeloid Leukemia (AML) &gt; / = 60 Years
Status: , Estimated PCD: 2007-06-01
Clinical trial
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Status: Active (not recruiting), Estimated PCD: 2026-05-01
Clinical trial
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Status: Completed, Estimated PCD: 2016-12-08
Clinical trial
A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin ( (Doxil®) in Patients With Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
Status: Recruiting, Estimated PCD: 2025-05-03
Clinical trial
Risk-Adapted Therapy for HIV-Associated Anal Cancer
Status: Recruiting, Estimated PCD: 2029-09-15
Clinical trial
A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma
Status: Recruiting, Estimated PCD: 2025-02-28
Clinical trial
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma
Status: Recruiting, Estimated PCD: 2029-12-31
Clinical trial
Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2025-01-31
Clinical trial
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Status: Active (not recruiting), Estimated PCD: 2021-03-31
Clinical trial
MATCH Treatment Subprotocol P: Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients With Tumors With PTEN Loss by IHC
Status: Active (not recruiting), Estimated PCD: 2024-11-30
Clinical trial
MATCH Treatment Subprotocol Z1E: Larotrectinib (LOXO-101) in Patients With Tumors With NTRK Fusions
Status: Active (not recruiting), Estimated PCD: 2025-03-24
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2023-09-30
Clinical trial
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Status: Active (not recruiting), Estimated PCD: 2023-10-02
Clinical trial
A Phase I/Randomized Phase II Study of Cediranib (NSC#732208) Versus Placebo in Combination With Cisplatin and Pemetrexed in Chemonaive Patients With Malignant Pleural Mesothelioma
Status: Active (not recruiting), Estimated PCD: 2018-06-01
Clinical trial
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
Status: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Status: Recruiting, Estimated PCD: 2025-11-30
Clinical trial
Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients With Recurrent Glioblastoma
Status: Not yet recruiting, Estimated PCD: 2028-07-15
Clinical trial
Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
Status: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination With Dual BRAF/MEK Inhibition in Patients With BRAF- Mutated Metastatic Melanoma Who Progressed on Prior BRAF/MEK Inhibitor Therapy
Status: Recruiting, Estimated PCD: 2024-12-04
Clinical trial
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
Status: Recruiting, Estimated PCD: 2036-12-01
Clinical trial
Phase II Trial of Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients With Soft Tissue Sarcoma
Status: , Estimated PCD: 2026-05-15
Clinical trial
Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer
Status: , Estimated PCD: 2027-02-23
Clinical trial
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Status: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
A Randomized International Phase 3 Trial of Imatinib and Chemotherapy With or Without Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or Philadelphia Chromosome-Like ABL-Class B-Cell Acute Lymphoblastic Leukemia
Status: Not yet recruiting, Estimated PCD: 2030-12-01
Clinical trial
A Phase 2 Study of Erdafitinib in Patients With Recurrent or Progressive IDH-Wild Type Glioma With an FGFR-TACC Gene Fusion
Status: Recruiting, Estimated PCD: 2026-10-23
Clinical trial
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Status: Active (not recruiting), Estimated PCD: 2023-09-15
Clinical trial
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Active (not recruiting), Estimated PCD: 2028-05-07
Clinical trial
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Status: Active (not recruiting), Estimated PCD: 2021-06-30
Clinical trial
Phase I Trial of [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Status: Not yet recruiting, Estimated PCD: 2029-01-01
Clinical trial
Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2026-10-10
Clinical trial
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2027-06-01
Clinical trial
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
Status: Recruiting, Estimated PCD: 2027-10-31
Clinical trial
Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism
Status: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors
Status: , Estimated PCD: 2027-05-28
Clinical trial
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Status: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2023-04-13
Clinical trial
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With &gt;/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2026-05-31
Clinical trial
A Randomized Phase II Study of AMG 510 (Sotorasib) With or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti (TM)) and Either Rituximab (Rituxan (R)) or Ruxience for Relapsed Hairy Cell Leukemia
Status: Active (not recruiting), Estimated PCD: 2023-07-07
Clinical trial
Pharmacokinetic-Driven Individualization of Pazopanib Therapy in Patients With Solid Tumors: A Phase I Study
Status: Active (not recruiting), Estimated PCD: 2015-12-31
Clinical trial
A Phase 1b/2 Study of Hu5F9-G4 (Magrolimab) in Combination With Mogamulizumab in Relapsed/Refractory Treated T-Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
Status: Active (not recruiting), Estimated PCD: 2023-04-14
Clinical trial
A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment After First-Line Treatment With Platinum-Gemcitabine-Nivolumab for Patients With Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)
Status: Recruiting, Estimated PCD: 2029-04-30
Clinical trial
Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Phase 2 and Biomarker Trial of Anti-TIGIT and Anti-PDL1 in Patients With Recurrent Glioblastoma
Status: Not yet recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Active (not recruiting), Estimated PCD: 2018-10-24
Clinical trial
Phase I Trial of Low-Dose Cyclophosphamide in Combination With Veliparib (ABT-888) in HER2/Neu-Negative Metastatic Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2016-11-25
Clinical trial
Phase I/II Trial of HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PD-L1/TGF-Beta Trap (M7824) in Subjects With HPV Positive Cancers
Status: Active (not recruiting), Estimated PCD: 2022-11-22
Clinical trial
Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase I Study of M3814 in Combination With MEC in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: , Estimated PCD: 2025-06-30
Clinical trial
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2019-01-25
Clinical trial
A Phase Ib Study of Osimertinib (AZD9291) and Telaglenastat (CB-839) HCl in Patients With EGFR Mutant Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
Phase 2 Trial of Single-Agent Ibrutinib (PCI-32765) in Relapsed or Refractory Follicular Lymphoma
Status: Active (not recruiting), Estimated PCD: 2016-06-03
Clinical trial
A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Status: Completed, Estimated PCD: 2022-12-20
Clinical trial
A Phase I Study of DS-8201a in Combination With Olaparib in HER2-Expressing Malignancies
Status: , Estimated PCD: 2024-06-30
Clinical trial
Phase II Trial of Radium-223 in Biochemically Recurrent Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-11-15
Clinical trial
Phase II Trial of Single Agent ABT-888 With Post-Progression Therapy of ABT-888 in Combination With Carboplatin in Patients With Stage IV BRCA-Associated Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Status: Active (not recruiting), Estimated PCD: 2025-05-10
Clinical trial
A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2014-07-01
Clinical trial
A Phase II Trial of SCH 727965 (NSC 747135) in Patients With Stage IV Melanoma
Status: Active (not recruiting), Estimated PCD: 2013-10-22
Clinical trial
Randomized Phase III Trial of Paclitaxel +Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2014-01-31
Clinical trial
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2017-07-31
Clinical trial
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status: Active (not recruiting), Estimated PCD: 2023-08-04
Clinical trial
A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2020-08-15
Clinical trial
A Phase I Trial of Osimertinib (AZD9291) and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
Status: Active (not recruiting), Estimated PCD: 2027-09-30
Clinical trial
A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Status: Active (not recruiting), Estimated PCD: 2023-06-01
Clinical trial
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-06-13
Clinical trial
A Randomized Phase I/II Trial of Fulvestrant and Abemaciclib in Combination With Copanlisib (FAC) Versus Fulvestrant and Abemaciclib Alone (FA) for Endocrine-Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FAC vs FA)
Status: Active (not recruiting), Estimated PCD: 2023-06-22
Clinical trial
Phase I Study of Recombinant Interleukin 15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in Subjects With Refractory Cancers
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).
Status: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
A Phase I Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T- Cells for Treating B-cell Malignancies
Status: Recruiting, Estimated PCD: 2028-12-30
Clinical trial
A Phase II Study of Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18F-DCFPyL-PET/CT in Newly Diagnosed Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2025-08-31
Clinical trial
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Status: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Phase I Study of Bintrafusp Alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Status: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
Phase II Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2025-01-31
Clinical trial
A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Follow-Up Evaluation for Gene-Therapy Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
Status: , Estimated PCD: 2035-04-01
Clinical trial
Phase II Trial of Enzalutamide and M9241 in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
Status: Recruiting, Estimated PCD: 2028-12-31
Clinical trial
BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination With Conventional Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
Status: , Estimated PCD: 2026-07-01
Clinical trial
Pilot Study of DS-8201a Pharmacodynamics in Patients With HER2-Expressing Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
A Study of Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18F-DCFPyL
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Status: Active (not recruiting), Estimated PCD: 2027-06-01
Clinical trial
Phase II Evaluation of Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in Patients With Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult With Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase 1b Trial of Teclistamab in Combination With Iberdomide for Relapsed/Refractory Multiple Myeloma
Status: Not yet recruiting, Estimated PCD: 2027-01-30
Clinical trial
A Phase I Study Evaluating the Safety of Cirtuvivint as Monotherapy and in Combination With ASTX727 and ASTX727 + Venetoclax in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Status: Not yet recruiting, Estimated PCD: 2027-01-01
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Status: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Status: , Estimated PCD: 2029-06-30
Clinical trial
Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Paclitaxel and Carboplatin With Ipatasertib as Initial Therapy of Ovarian Cancer PTMA 100805
Status: Recruiting, Estimated PCD: 2025-01-30
Clinical trial
Phase II Randomized Trial of Immunotherapy Versus Immunotherapy and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (IMMORTAL)
Status: Active (not recruiting), Estimated PCD: 2025-04-30
Clinical trial
Molecular Analysis for Therapy Choice (MATCH)
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2015-01-31
Clinical trial
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Status: Recruiting, Estimated PCD: 2025-02-28